| Year |
Citation |
Score |
| 2019 |
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology. 10: 1943. PMID 31475004 DOI: 10.3389/Fimmu.2019.01943 |
0.357 |
|
| 2019 |
Guillon R, Rahimova R, Preeti, Egron D, Rouanet S, Dumontet C, Aghajari N, Jordheim LP, Chaloin L, Peyrottes S. Lead optimization and biological evaluation of fragment-based cN-II inhibitors. European Journal of Medicinal Chemistry. 168: 28-44. PMID 30798051 DOI: 10.1016/J.Ejmech.2019.02.040 |
0.317 |
|
| 2019 |
Alameh G, Emptoz-Bonneton A, Rolland de Ravel M, Matera EL, Mappus E, Balaguer P, Rocheblave L, Lomberget T, Dumontet C, Le Borgne M, Pugeat M, Grenot C, Cuilleron CY. In vitro modulation of multidrug resistance by pregnane steroids and in vivo inhibition of tumour development by 7α-OBz-11α(R)-OTHP-5β-pregnanedione in K562/R7 and H295R cell xenografts. Journal of Enzyme Inhibition and Medicinal Chemistry. 34: 684-691. PMID 30777494 DOI: 10.1080/14756366.2019.1575825 |
0.312 |
|
| 2019 |
Boyle EM, Davies FE, Deshpande S, Tytarenko RG, Ashby C, Wang Y, Wardell CP, Bauer MA, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Zangari M, Williams L, Facon T, ... Dumontet C, et al. Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma Blood. 134: 4333-4333. DOI: 10.1182/Blood-2019-126679 |
0.334 |
|
| 2018 |
Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C. Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology. 102: 161-168. PMID 30048976 DOI: 10.1159/000491587 |
0.336 |
|
| 2018 |
Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, ... ... Dumontet C, et al. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Research. PMID 29559475 DOI: 10.1158/0008-5472.Can-17-1900 |
0.329 |
|
| 2018 |
Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford MW, Ashby C, Bauer MA, Johnson SK, Wardell CP, Weinhold N, Hoering A, Dumontet C, Facon T, Schinke CD, Thanendrarajan S, et al. Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior Blood. 132: 4457-4457. DOI: 10.1182/Blood-2018-99-119113 |
0.346 |
|
| 2018 |
Boyle EM, Ashby C, Tytarenko RG, Wang Y, Bauer MA, Deshpande S, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Wardell C, Weinhold N, Facon T, Dumontet C, Morgan G, et al. Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria Blood. 132: 4456-4456. DOI: 10.1182/Blood-2018-99-117193 |
0.301 |
|
| 2018 |
Barret JM, Meseure D, Bataillon G, Andersson N, Auguste A, Dubreuil O, Färkkilä A, Perrial E, Bossard C, Loison E, Jarry A, Nicolas A, Lemée F, Gaillard S, Lahmar M, ... ... Dumontet C, et al. Abstract 774: Anti-Müllerian hormone type II receptor (AMHRII) found expressed in human non-gynecological solid tumors, suggesting potential broader applications for anti-AMHRII-based therapy Cancer Research. 78: 774-774. DOI: 10.1158/1538-7445.Am2018-774 |
0.306 |
|
| 2018 |
Cadassou O, Raza MZ, Cros-Perrial E, Armanet C, Gudefin L, Chettab K, Manié S, Dumontet C, Jordheim LP. Abstract 3164: Impact of cN-II and CD73 inhibition on cancer cell migration Tumor Biology. DOI: 10.1158/1538-7445.Am2018-3164 |
0.306 |
|
| 2017 |
Bricard G, Cadassou O, Cassagnes LE, Cros-Perrial E, Payen-Gay L, Puy JY, Lefebvre-Tournier I, Tozzi MG, Dumontet C, Jordheim LP. The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget. 8: 67380-67393. PMID 28978040 DOI: 10.18632/Oncotarget.18653 |
0.319 |
|
| 2017 |
Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. PMID 28210004 DOI: 10.1038/Leu.2017.60 |
0.317 |
|
| 2016 |
Rocheblave L, de Ravel MR, Monniot E, Tavenard J, Cuilleron CY, Grenot C, Radix S, Matera EL, Dumontet C, Walchshofer N. Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. Steroids. 116: 5-12. PMID 27697501 DOI: 10.1016/J.Steroids.2016.09.017 |
0.322 |
|
| 2016 |
Sauveur J, Chettab A, matera E, Cleret A, Savina A, Dumontet C. Abstract 309: Mechanisms of resistance to trastuzumab emtansine in gastric cancer Cancer Research. 76: 309-309. DOI: 10.1158/1538-7445.Am2016-309 |
0.368 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 7539. PMID 26198393 DOI: 10.1038/Ncomms8539 |
0.319 |
|
| 2015 |
Cividini F, Cros-Perrial E, Pesi R, Machon C, Allegrini S, Camici M, Dumontet C, Jordheim LP, Tozzi MG. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5′-nucleotidase II International Journal of Biochemistry and Cell Biology. 65: 222-229. PMID 26079827 DOI: 10.1016/J.Biocel.2015.06.011 |
0.358 |
|
| 2015 |
Jordheim LP, Puy JY, Cros-Perrial E, Peyrottes S, Lefebvre I, Périgaud C, Dumontet C. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. Analytical and Bioanalytical Chemistry. PMID 25998135 DOI: 10.1007/S00216-015-8757-4 |
0.338 |
|
| 2015 |
Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, Cros-Perrial E, Dumontet C, Jordheim LP, Tozzi MG. The purine analog fludarabine acts as a cytosolic 5′-nucleotidase II inhibitor Biochemical Pharmacology. 94: 63-68. PMID 25656700 DOI: 10.1016/J.Bcp.2015.01.010 |
0.347 |
|
| 2015 |
Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, Dumontet C. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica. 100: e204-6. PMID 25637052 DOI: 10.3324/Haematol.2014.120113 |
0.312 |
|
| 2015 |
Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. Leukemia & Lymphoma. 56: 622-9. PMID 24884314 DOI: 10.3109/10428194.2014.927453 |
0.344 |
|
| 2015 |
Hirz T, Esmenjaud J, Evesque A, Mathe-Poloni D, Dumontet C. Abstract 5014: Neutrophils protect B-cell lymphomas against chemotherapy via cell-cell interactions mediated by CD44 and ICAM1 receptors Immunology. 75: 5014-5014. DOI: 10.1158/1538-7445.Am2015-5014 |
0.334 |
|
| 2014 |
Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clinical and Experimental Pharmacology & Physiology. 41: 817-24. PMID 25115435 DOI: 10.1111/1440-1681.12282 |
0.306 |
|
| 2014 |
Chaabane F, Krifa M, Matera E, Loussaeif A, Dijoux-Franca MG, Ghedira K, Dumontet C, Chekir-Ghedira L. In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 35: 8991-8. PMID 24903378 DOI: 10.1007/S13277-014-2129-0 |
0.315 |
|
| 2014 |
Boespflug A, Thomas L, Rousset P, Dumontet C, Caramel J, Ferraro-Peyret C, Bringuier PP, Balme B, Dalle S. Abstract 5602: BRAF V600 mutated allelic specific imbalance (MASI) impact on sensitivity to vemurafenib Cancer Research. 74: 5602-5602. DOI: 10.1158/1538-7445.Am2014-5602 |
0.357 |
|
| 2014 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Campa D, Aftab B, Bracci P, Buda G, Caswell J, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Hunstman S, et al. Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients Cancer Research. 74: 5078-5078. DOI: 10.1158/1538-7445.Am2014-5078 |
0.315 |
|
| 2014 |
Duong MN, Cleret A, Matera E, Chettab K, Poloni D, Valsesia-Wittmann S, Clémenceau B, Dumontet C. Abstract 3783: Adipocytes inhibit trastuzumab-mediated ADCC via induction of GDF15 Cancer Research. 74: 3783-3783. DOI: 10.1158/1538-7445.Am2014-3783 |
0.377 |
|
| 2014 |
Bossard C, Dumontet C, Jordheim LP. Abstract 3613: Opposite effects of adipocytes and adenosine on hematological cancer cell survival and proliferationin vitro Cancer Research. 74: 3613-3613. DOI: 10.1158/1538-7445.Am2014-3613 |
0.365 |
|
| 2013 |
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, ... ... Dumontet C, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Molecular Cancer Therapeutics. 12: 2031-42. PMID 23873847 DOI: 10.1158/1535-7163.Mct-12-1182 |
0.313 |
|
| 2013 |
Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3556-66. PMID 23674497 DOI: 10.1158/1078-0432.Ccr-12-3134 |
0.323 |
|
| 2013 |
Honorat M, Terreux R, Falson P, Di Pietro A, Dumontet C, Payen L. Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models. Bmc Structural Biology. 13: 7. PMID 23641929 DOI: 10.1186/1472-6807-13-7 |
0.342 |
|
| 2013 |
Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Molecular Pharmacology. 84: 12-24. PMID 23580445 DOI: 10.1124/Mol.112.082347 |
0.304 |
|
| 2013 |
Wetzel M, Nicolazzi C, Vallée F, Deckert J, Dumontet C, Plesa A, Kannt A, Mikol V, Chiron M, Vincent L, Blanc V. Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Cancer Research. 73: 4735-4735. DOI: 10.1158/1538-7445.Am2013-4735 |
0.33 |
|
| 2013 |
Osdal T, Jordheim LP, Popa M, Vikebø LM, Sulen A, Bedringaas SL, Sandvold ML, Booij B, Bruserud Ø, Gjertsen BT, Dumontet C, McCormack E. Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML. Cancer Research. 73: 3274-3274. DOI: 10.1158/1538-7445.Am2013-3274 |
0.31 |
|
| 2012 |
Gonçalves A, Trédan O, Villanueva C, Dumontet C. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. Bulletin Du Cancer. 99: 1183-91. PMID 23247898 DOI: 10.1684/Bdc.2012.1669 |
0.307 |
|
| 2012 |
Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, ... ... Dumontet C, et al. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Research. 72: 4429-39. PMID 22761334 DOI: 10.1158/0008-5472.Can-11-3342 |
0.323 |
|
| 2012 |
Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau J, Labussière-Wallet H, Nicolini FE, Dumontet C, Mohty M, Attal M, et al. Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. Blood. 120: 3116-3116. DOI: 10.1182/Blood.V120.21.3116.3116 |
0.322 |
|
| 2012 |
Jordheim L, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Salles G, Dumontet C. Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma Blood. 120: 1616-1616. DOI: 10.1182/Blood.V120.21.1616.1616 |
0.325 |
|
| 2012 |
Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Michallet M, Dumontet C, Thomas X. Higher Percentage of CD34+CD38− Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML Blood. 120: 1485-1485. DOI: 10.1182/Blood.V120.21.1485.1485 |
0.323 |
|
| 2012 |
Jordheim LP, Marton Z, Rhimi M, Chaloin L, Cros-Perrial E, Lionne C, Peyrottes S, Aghajari N, Dumontet C. Abstract 3835: Identification and characterization of inhibitors of 5′-nucleotidase cN-II issued from virtual screening Cancer Research. 72: 3835-3835. DOI: 10.1158/1538-7445.Am2012-3835 |
0.307 |
|
| 2011 |
Honorat M, Mesnier A, Vendrell J, Di Pietro A, Lin V, Dumontet C, Cohen P, Payen L. MRP8/ABCC11 expression is regulated by dexamethasone in breast cancer cells and is associated to progesterone receptor status in breast tumors. International Journal of Breast Cancer. 2011: 807380. PMID 22332017 DOI: 10.4061/2011/807380 |
0.309 |
|
| 2011 |
Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussière H, Tigaud I, Ducastelle S, Nicolini F, Dumontet C, Michallet M. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clinical Lymphoma, Myeloma & Leukemia. 11: 342-9. PMID 21816372 DOI: 10.1016/J.Clml.2011.06.003 |
0.334 |
|
| 2011 |
Tagoug I, Sauty De Chalon A, Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. Plos One. 6: e22641. PMID 21799925 DOI: 10.1371/Journal.Pone.0022641 |
0.304 |
|
| 2011 |
Doléans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, Dumontet C, Freney J, Jordheim LP. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 30: 1249-56. PMID 21494911 DOI: 10.1007/S10096-011-1220-3 |
0.307 |
|
| 2011 |
Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M, Thomas X. Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases. Leukemia Research. 35: 1027-31. PMID 21397944 DOI: 10.1016/J.Leukres.2011.02.015 |
0.321 |
|
| 2011 |
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Molecular Cancer Therapeutics. 10: 178-85. PMID 21220500 DOI: 10.1158/1535-7163.Mct-10-0385 |
0.308 |
|
| 2011 |
Jordheim LP, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. The Lancet. Oncology. 12: 693-702. PMID 21163702 DOI: 10.1016/S1470-2045(10)70244-8 |
0.331 |
|
| 2011 |
Jordheim LP, Plesa A, Dreano M, Cros-Perrial E, Keime C, Herveau S, Demangel D, Vendrell JA, Dumontet C. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. Cancer Chemotherapy and Pharmacology. 68: 97-105. PMID 20844879 DOI: 10.1007/S00280-010-1458-Y |
0.328 |
|
| 2010 |
Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer. Journal International Du Cancer. 126: 545-62. PMID 19609946 DOI: 10.1002/Ijc.24750 |
0.37 |
|
| 2010 |
Tagoug I, Plesa A, Vendrell J, Dumontet C. Effect of Imids on Gene Expression Profiles of Fresh Human Myeloma Cells Blood. 116: 5013-5013. DOI: 10.1182/Blood.V116.21.5013.5013 |
0.373 |
|
| 2010 |
Tagoug I, Jordheim L, Huber A, Herveau S, Matera E, Manié S, Dumontet C. Insulin-Like Growth Factor 1 Potentiates the Cytotoxic Activity of Bortezomib Against Myeloma Cells Blood. 116: 3987-3987. DOI: 10.1182/Blood.V116.21.3987.3987 |
0.343 |
|
| 2010 |
Reslan L, Dalle S, Tournebize C, Herveau S, Cros E, Dumontet C. Comparison of Cytotoxic Mechanisms of Anti-CD20 Antibodies GA101 and Rituximab Against Fresh Chronic Lymphocytic Leukemia Cells Blood. 116: 2467-2467. DOI: 10.1182/Blood.V116.21.2467.2467 |
0.329 |
|
| 2010 |
Rouba H, Herveau S, Matera E, Laurier J, Dumontet C. 98: Reduced content of Tubulin binding cofactor C (TBCC) in breast cancer cells modifies progression into cell cycle and influences response to treatments Bulletin Du Cancer. 97: S79-S80. DOI: 10.1016/S0007-4551(15)31191-7 |
0.309 |
|
| 2009 |
Hébrard C, Cros-Perrial E, Clausen AR, Dumontet C, Piskur J, Jordheim LP. Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells. Nucleosides, Nucleotides & Nucleic Acids. 28: 1068-75. PMID 20183574 DOI: 10.1080/15257770903368393 |
0.32 |
|
| 2009 |
Beghin A, Belin S, Hage-Sleiman R, Hage Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon MF, Diaz JJ, Dumontet C. ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. Plos One. 4: e7478. PMID 19829707 DOI: 10.1371/Journal.Pone.0007478 |
0.309 |
|
| 2009 |
Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet C, Tuszynski J. Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. Journal of Molecular Graphics & Modelling. 28: 113-30. PMID 19473860 DOI: 10.1016/J.Jmgm.2009.04.009 |
0.309 |
|
| 2009 |
Diab R, Jordheim LP, Degobert G, Peyrottes S, Périgaud C, Dumontet C, Fessi H. Preparation, characterization and in vitro evaluation of a new nucleotide analogue prodrug cyclodextrin inclusion complexes. Journal of Nanoscience and Nanotechnology. 9: 295-300. PMID 19441310 DOI: 10.1166/Jnn.2009.J075 |
0.311 |
|
| 2009 |
Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 851-7. PMID 19188155 DOI: 10.1158/1078-0432.Ccr-08-1685 |
0.346 |
|
| 2009 |
Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology. 42: 87-103. PMID 18984771 DOI: 10.1677/Jme-08-0076 |
0.387 |
|
| 2009 |
Plesa A, Lesca G, Dhedin N, Sobh M, Michallet AS, Nicolini FE, Merle-Beral H, Garban F, Leblond V, Sagorny K, Morisset S, Calender A, Dumontet C, Leporrier M, Sutton L, et al. Expression of the Chemokine Receptor CXCR4, CXCL12G801A Gene polymorphism and SDF1 Plasma Levels in B-Cell Chronic Lymphocytic Leukemia (B-CLL): Correlation with PBSC Mobilisation, Disease Characteristics and Outcome. Blood. 114: 2336-2336. DOI: 10.1182/Blood.V114.22.2336.2336 |
0.362 |
|
| 2009 |
Jordheim LP, Degobert G, Diab R, Peyrottes S, Périgaud C, Dumontet C, Fessi H. Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta- cyclodextrin Journal of Inclusion Phenomena and Macrocyclic Chemistry. 63: 11-16. DOI: 10.1007/S10847-008-9483-8 |
0.304 |
|
| 2008 |
Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, Cohen PA. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Science. 99: 1992-2003. PMID 19016759 DOI: 10.1016/S1359-6349(08)71494-0 |
0.386 |
|
| 2008 |
Béghin A, Matera EL, Brunet-Manquat S, Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line Cell Cycle. 7: 3074-3082. PMID 18818514 DOI: 10.4161/Cc.7.19.6777 |
0.359 |
|
| 2008 |
Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4511-6. PMID 18628466 DOI: 10.1158/1078-0432.Ccr-07-4741 |
0.319 |
|
| 2008 |
Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology Anti-Cancer Agents in Medicinal Chemistry. 8: 523-532. PMID 18537534 DOI: 10.2174/187152008784533071 |
0.316 |
|
| 2008 |
Honorat M, Mesnier A, Vendrell J, Guitton J, Bieche I, Lidereau R, Kruh GD, Dumontet C, Cohen P, Payen L. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocrine-Related Cancer. 15: 125-38. PMID 18310281 DOI: 10.1677/Erc-07-0189 |
0.341 |
|
| 2008 |
Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? The Lancet Oncology. 9: 168-175. PMID 18237851 DOI: 10.1016/S1470-2045(08)70029-9 |
0.343 |
|
| 2008 |
Plesa C, Le Q, Chelghoum Y, Elhamri M, Tigaud I, Anglaret B, Ducastelle S, Perrin M, Nicolini F, Belhabri A, Troncy J, Thiebaut A, Hayette S, Revesz D, Wattel E, ... Dumontet C, et al. Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience Clinical Leukemia. 2: 198-204. DOI: 10.3816/Clk.2008.N.025 |
0.314 |
|
| 2007 |
Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemotherapy and Pharmacology. 60: 27-34. PMID 17021819 DOI: 10.1007/S00280-006-0343-1 |
0.301 |
|
| 2007 |
Dalle MS, Dumontet C. Rituximab: Mechanism of action and resistance Bulletin Du Cancer. 94: 198-202. DOI: 10.1684/Bdc.2007.0201 |
0.353 |
|
| 2007 |
Plesa A, Le Q, Revesz D, Thomas X, Ducastelle S, Nicolini FE, Michallet A, Mollet I, Dubois V, Clark M, Dumontet C, Raus N, Michallet M. Correlation between MRD and Chimerism Kinetics in CLL Patients after Myeloablative and Non-Myeloablative Allogeneic Hematopoïetic Stem Cell Transplantation. Blood. 110: 5048-5048. DOI: 10.1182/Blood.V110.11.5048.5048 |
0.315 |
|
| 2007 |
Plesa C, Le Q, Chelghoum Y, Elhamri M, Tigaud I, Anglaret B, Ducastelle S, Perrin M, Nicolini F, Belhabri A, Troncy J, Thiebaut A, Revesz D, Wattel E, Dumontet C, et al. Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. Blood. 110: 4352-4352. DOI: 10.1182/Blood.V110.11.4352.4352 |
0.316 |
|
| 2006 |
Dumontet C, Thomas L, Bérard F, Gimonet JF, Coiffier B. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma Bulletin Du Cancer. 93. PMID 17145574 DOI: 10.1684/Bdc.2006.0148 |
0.32 |
|
| 2006 |
Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Céligny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C. Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Annals of Oncology. 18: 370-375. PMID 17074972 DOI: 10.1093/Annonc/Mdl395 |
0.301 |
|
| 2006 |
Koubeissi A, Raad I, Ettouati L, Guilet D, Dumontet C, Paris J. Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins Bioorganic and Medicinal Chemistry Letters. 16: 5700-5703. PMID 16950619 DOI: 10.1016/J.Bmcl.2006.07.059 |
0.301 |
|
| 2006 |
Moreau P, Voillat L, Benboubker L, Dumontet C, Mathiot C, Hulin C, Robillard N, Loiseau HA, Herault O, Garnache F, Varoqueaux N, Harousseau J, Bataille R. Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. Blood. 108: 3577-3577. DOI: 10.1182/Blood.V108.11.3577.3577 |
0.353 |
|
| 2005 |
Sève P, Isaac S, Trédan O, Souquet P, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller E, Dumontet C. Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy Clinical Cancer Research. 11: 5481-5486. PMID 16061864 DOI: 10.1158/1078-0432.Ccr-05-0285 |
0.351 |
|
| 2005 |
Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC) Leukemia and Lymphoma. 46: 335-346. PMID 15621823 DOI: 10.1080/10428190400015683 |
0.352 |
|
| 2004 |
Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bulletin Du Cancer. 91: E81-112. PMID 15568225 |
0.698 |
|
| 2004 |
Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D, Lemieux B, Traullé C, Espinouse D, Salles G, Coiffier B. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leukemia & Lymphoma. 45: 711-4. PMID 15160944 DOI: 10.1080/10428190310001615675 |
0.348 |
|
| 2004 |
Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. Bmc Pharmacology. 4: 8. PMID 15157282 DOI: 10.1186/1471-2210-4-8 |
0.367 |
|
| 2003 |
Jordheim L, Galmarini CM, Dumontet C. Drug resistance to cytotoxic nucleoside analogues Current Drug Targets. 4: 443-460. PMID 12866659 DOI: 10.2174/1389450033490957 |
0.323 |
|
| 2003 |
Thieblemont C, Dumontet C, Bouafia F, Hequet O, Arnaud P, Espinouse D, Felman P, Berger F, Salles G, Coiffier B. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leukemia & Lymphoma. 44: 257-62. PMID 12688342 DOI: 10.1080/1042819021000035680 |
0.308 |
|
| 2003 |
Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C, Tranchand B, Berger E, Lucas C, Guyotat D, Coiffier B. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients Annals of Oncology. 14: 615-622. PMID 12649110 DOI: 10.1093/Annonc/Mdg158 |
0.314 |
|
| 2002 |
Thieblemont C, Chettab K, Felman P, Callet-Bauchu E, Traverse-Glehen A, Berger F, Dumontet C, Cerutti C, Baseggio L, Salles G, Paultre C, Coiffier B, McGregor J. Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia. 16: 2326-2329. PMID 12399979 DOI: 10.1038/Sj.Leu.2402691 |
0.311 |
|
| 2002 |
Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, Arcache J, Callet-Bauchu E, Salles G, Coiffier B. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clinical Lymphoma. 3: 41-7. PMID 12141954 DOI: 10.3816/Clm.2002.N.010 |
0.337 |
|
| 2001 |
Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E, Mackey JR, Dumontet C. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia Blood. 98: 1922-1926. PMID 11535530 DOI: 10.1182/Blood.V98.6.1922 |
0.348 |
|
| 2001 |
Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology. 113: 772-8. PMID 11380469 DOI: 10.1046/J.1365-2141.2001.02795.X |
0.339 |
|
| 2001 |
Dumontet C, Drai J, Thieblemont C, Hequet O, Espinouse D, Bouafia F, Salles G, Coiffier B. The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide British Journal of Haematology. 112: 405-409. PMID 11167839 DOI: 10.1046/J.1365-2141.2001.02595.X |
0.331 |
|
| 2000 |
Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors Leukemia. 14: 2159-2165. PMID 11187906 DOI: 10.1038/Sj.Leu.2401955 |
0.332 |
|
| 2000 |
Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski M, Coiffier B, Salles G. Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System Journal of Clinical Oncology. 18: 325-325. PMID 10637246 DOI: 10.1200/Jco.2000.18.2.325 |
0.307 |
|
| 1999 |
Dumontet C, Fabianowska-Majewska K, Mantincic D, Bauchu EC, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, Mackey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology. 106: 78-85. PMID 10444166 DOI: 10.1046/J.1365-2141.1999.01509.X |
0.328 |
|
| 1999 |
Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1061-70. PMID 10071301 DOI: 10.1200/Jco.1999.17.3.1061 |
0.536 |
|
| 1998 |
Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients Annals of Oncology. 9: 1109-1115. PMID 9834824 DOI: 10.1023/A:1008498705032 |
0.346 |
|
| 1998 |
Ketterer N, Salles G, Moullet I, Dumontet C, Eljaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard E, Samaha H, Rigal D, Coiffier B. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies British Journal of Haematology. 103: 235-241. PMID 9792315 DOI: 10.1046/J.1365-2141.1998.00960.X |
0.368 |
|
| 1998 |
Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 12: 1281-1287. PMID 9697885 DOI: 10.1038/Sj.Leu.2401121 |
0.337 |
|
| 1998 |
Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard E, Bouafia F, Coiffier B. High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation Blood. 91: 3148-3155. DOI: 10.1182/Blood.V91.9.3148.3148_3148_3155 |
0.332 |
|
| 1997 |
Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, Bouafia F, Berger F, Felman P, Coiffier B. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma Annals of Oncology. 8: 701-704. PMID 9296227 DOI: 10.1023/A:1008278605751 |
0.35 |
|
| 1997 |
Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients Journal of Clinical Oncology. 15: 1587-1594. PMID 9193357 DOI: 10.1200/Jco.1997.15.4.1587 |
0.305 |
|
| 1997 |
Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Journal of Clinical Oncology. 15: 499-508. PMID 9053471 DOI: 10.1200/Jco.1997.15.2.499 |
0.306 |
|
| 1997 |
Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. The Journal of Biological Chemistry. 272: 5974-82. PMID 9038218 DOI: 10.1074/Jbc.272.9.5974 |
0.697 |
|
| 1997 |
Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Brière J. Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome Blood. 90: 3727-3734. DOI: 10.1182/Blood.V90.9.3727 |
0.354 |
|
| 1996 |
Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH, Sikic BI. Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton. 35: 49-58. PMID 8874965 DOI: 10.1002/(Sici)1097-0169(1996)35:1<49::Aid-Cm4>3.0.Co;2-D |
0.541 |
|
| 1996 |
Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Research. 56: 1091-7. PMID 8640766 |
0.491 |
|
| 1995 |
Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncology Research. 7: 517-27. PMID 8866664 |
0.531 |
|
| 1995 |
Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Journal of the National Cancer Institute. 87: 1593-602. PMID 7563202 DOI: 10.1093/Jnci/87.21.1593 |
0.57 |
|
| 1994 |
Geriniere L, Bastion Y, Dumontet C, Salles G, Espinouse D, Coiffier B. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients Annals of Oncology. 5: 437-440. PMID 7521205 DOI: 10.1093/Oxfordjournals.Annonc.A058876 |
0.304 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, ... ... Dumontet C, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 143: 664-74.e1-6. PMID 22705007 DOI: 10.1053/J.Gastro.2012.06.006 |
0.3 |
|
| 2011 |
Honorat M, Falson P, Terreux R, Di Pietro A, Dumontet C, Payen L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Current Drug Metabolism. 12: 268-77. PMID 21470105 DOI: 10.2174/138920011795101804 |
0.299 |
|
| 2000 |
Michallet M, Thiébaut A, Philip I, Charrin C, Vigouroux C, Thomas X, Bilger K, Belhabri A, Guyotat D, Corront B, Salles B, Dumontet C, Péaud P, Vilque J, Devidas A, et al. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α Leukemia. 14: 2064-2069. PMID 11187894 DOI: 10.1038/Sj.Leu.2401956 |
0.299 |
|
| 2010 |
Julia F, Thomas L, Dumontet C, Dalle S. Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anti-Cancer Agents in Medicinal Chemistry. 10: 661-5. PMID 21235437 DOI: 10.2174/187152010794479834 |
0.298 |
|
| 2016 |
Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget. PMID 27437873 DOI: 10.18632/Oncotarget.10665 |
0.298 |
|
| 2016 |
Cornet S, Mathé D, Chettab K, Evesque A, Matera EL, Tredan O, Dumontet C. Pegfilgrastim enhances the antitumor effect of therapeutic monoclonal antibodies. Molecular Cancer Therapeutics. PMID 26988998 DOI: 10.1158/1535-7163.Mct-15-0759 |
0.298 |
|
| 2008 |
Trédan O, Grantab R, Dumontet C. Can tumor hypoxia be turned into a chemotherapeutic advantage? Bulletin Du Cancer. 95: 528-534. PMID 18541517 DOI: 10.1684/Bdc.2008.0637 |
0.298 |
|
| 2013 |
Plesa A, Chelghoum Y, Mattei E, Labussière H, Elhamri M, Cannas G, Morisset S, Tagoug I, Michallet M, Dumontet C, Thomas X. Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. World Journal of Stem Cells. 5: 196-204. PMID 24179607 DOI: 10.4252/Wjsc.V5.I4.196 |
0.295 |
|
| 2007 |
Bayet C, Fazio C, Darbour N, Berger O, Raad I, Chaboud A, Dumontet C, Guilet D. Modulation of P-glycoprotein activity by acridones and coumarins from Citrus sinensis Phytotherapy Research. 21: 386-390. PMID 17236173 DOI: 10.1002/Ptr.2081 |
0.294 |
|
| 2006 |
Raad I, Terreux R, Richomme P, Matera EL, Dumontet C, Raynaud J, Guilet D. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein Bioorganic and Medicinal Chemistry. 14: 6979-6987. PMID 16824763 DOI: 10.1016/J.Bmc.2006.06.026 |
0.292 |
|
| 2008 |
Michallet M, Sobh M, Le QH, Barraco F, Dumontet C, Chelghoum Y, Nicolas-Virelizier E, Thomas X, Praire A, Plesa C, Cannas G, Nicolini FE, Troncy J. Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade®): A Study on Efficacy, Tolerance, Survival and Time to Progression Blood. 112: 5197-5197. DOI: 10.1182/Blood.V112.11.5197.5197 |
0.291 |
|
| 1997 |
Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Brière J, Coiffier B. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 2945-53. PMID 9256139 DOI: 10.1200/Jco.1997.15.8.2945 |
0.291 |
|
| 2004 |
Lenain C, Dumontet C, Gargi T, Chassagne C, Berger F, Perol D, Garnier M, Coiffier B, Blay JY. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma Hematology Journal. 5: 403-409. PMID 15448666 DOI: 10.1038/Sj.Thj.6200545 |
0.291 |
|
| 2002 |
Barron D, Di Pietro A, Dumontet C, McIntosh DB. Isoprenoid flavonoids are new leads in the modulation of chemoresistance Phytochemistry Reviews. 1: 325-332. DOI: 10.1023/A:1026099520073 |
0.29 |
|
| 2011 |
Gallier F, Lallemand P, Meurillon M, Jordheim LP, Dumontet C, Périgaud C, Lionne C, Peyrottes S, Chaloin L. Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues. Plos Computational Biology. 7: e1002295. PMID 22174667 DOI: 10.1371/Journal.Pcbi.1002295 |
0.29 |
|
| 2014 |
Dargaud YG, Fouassier M, Ducastelle S, Moreau P, Dumontet C, Michallet M, Bordet J, Negrier C. The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability? Blood. 124: 2037-2037. DOI: 10.1182/Blood.V124.21.2037.2037 |
0.29 |
|
| 2015 |
Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, GarcÃa-Sanz R, Buda G, ... ... Dumontet C, et al. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer. Journal International Du Cancer. 136: E351-8. PMID 25066524 DOI: 10.1002/Ijc.29101 |
0.29 |
|
| 2018 |
Dumontet C, Peyrottes S, Rabeson C, Cros-Perrial E, Géant PY, Chaloin L, Jordheim LP. CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. European Journal of Medicinal Chemistry. 157: 1051-1055. PMID 30176535 DOI: 10.1016/J.Ejmech.2018.08.035 |
0.29 |
|
| 2007 |
Legrand O, Vidriales MB, Thomas X, Dumontet C, Vekhoff A, Morariu-Zamfir R, Lambert J, Miguel JFS, Marie J. An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML). Blood. 110: 1850-1850. DOI: 10.1182/Blood.V110.11.1850.1850 |
0.29 |
|
| 2006 |
Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C, Mackey JR. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 107: 2698-705. PMID 17063500 DOI: 10.1002/Cncr.22300 |
0.289 |
|
| 2011 |
Dumontet C. [Antitubulin agents]. Bulletin Du Cancer. 98: 1275-85. PMID 22023745 DOI: 10.1684/Bdc.2011.1469 |
0.287 |
|
| 2009 |
Sève P, Mackey J, Sawyer M, Lesimple T, Fouchardière CdL, Broussolle C, Dumontet C, Ray-Coquard I. Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" study. Bulletin Du Cancer. 96: 10007-10017. PMID 19435692 DOI: 10.1684/Bdc.2009.0870 |
0.286 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, et al. Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 10203. PMID 26648255 DOI: 10.1038/Ncomms10203 |
0.285 |
|
| 2009 |
Minvielle S, Keime C, Magrangeas F, Vendrell J, Gouraud W, Morais SRd, Montesinos S, Dumontet C, Avet-Loiseau H. A High Density Polymorphism Analysis of Factors Correlated with Neurotoxicity to Bortezomib in Patients with Multiple Myeloma. Blood. 114: 4816-4816. DOI: 10.1182/Blood.V114.22.4816.4816 |
0.284 |
|
| 2010 |
Dalle S, Thomas L, Balme B, Dumontet C, Thieblemont C. Primary cutaneous marginal zone lymphoma. Critical Reviews in Oncology/Hematology. 74: 156-62. PMID 19819717 DOI: 10.1016/J.Critrevonc.2009.09.003 |
0.283 |
|
| 2011 |
Plesa A, Thomas X, Le QH, Michallet A, Dubois V, Dumontet C, Michallet M. A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation Journal of Biomedical Science and Engineering. 4: 173-179. DOI: 10.4236/Jbise.2011.43024 |
0.282 |
|
| 2011 |
Aouali N, El Btaouri H, Dumontet C, Eddabra L, Malagarie-Cazenave S, Madoulet C, Morjani H. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncology Reports. 25: 1161-7. PMID 21318225 DOI: 10.3892/Or.2011.1180 |
0.282 |
|
| 1999 |
Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C, Neidhardt-Berard E, Bouafia F, Coiffier B, Salles G. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. The American Journal of Medicine. 106: 191-197. PMID 10230749 DOI: 10.1016/S0002-9343(98)00409-4 |
0.28 |
|
| 2012 |
Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J, Doléans-Jordheim A. Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. International Journal of Antimicrobial Agents. 39: 444-7. PMID 22445492 DOI: 10.1016/J.Ijantimicag.2012.01.019 |
0.28 |
|
| 2020 |
Sauveur J, Conilh L, Beaumel S, Chettab K, Jordheim LP, Matera EL, Dumontet C. Characterization of T-DM1-resistant breast cancer cells. Pharmacology Research & Perspectives. 8: e00617. PMID 32583565 DOI: 10.1002/prp2.617 |
0.279 |
|
| 2010 |
Arnaud O, Koubeissi A, Ettouati L, Terreux R, Alamé G, Grenot C, Dumontet C, Di Pietro A, Paris J, Falson P. Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. Journal of Medicinal Chemistry. 53: 6720-9. PMID 20731360 DOI: 10.1021/Jm100839W |
0.278 |
|
| 1992 |
Dumontet C, Bastion Y, Felman P, Ffrench M, Blanc M, Peaud PY, Coiffier B. Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen Annals of Oncology. 3: 639-644. PMID 1280459 DOI: 10.1093/Oxfordjournals.Annonc.A058293 |
0.277 |
|
| 2006 |
Harland E, Dalle S, Balme B, Dumontet C, Thomas L. Ungueotropic T-cell lymphoma Archives of Dermatology. 142: 1071-1073. PMID 16924067 DOI: 10.1001/Archderm.142.8.1071 |
0.275 |
|
| 2015 |
Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP. The druggability of intracellular nucleotide-degrading enzymes. Cancer Chemotherapy and Pharmacology. PMID 26614508 DOI: 10.1007/S00280-015-2921-6 |
0.274 |
|
| 2019 |
Raza MZ, Cadassou O, Cros-Perrial E, Puisieux A, Dumontet C, Jordheim LP. Abstract 1778: 5’-nucleotidases are involved in the biology of human lung cancer cell lines Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1778 |
0.273 |
|
| 2016 |
Macauda A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A, Lopez JM, Watek M, ... ... Dumontet C, et al. Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer. PMID 27718532 DOI: 10.1002/Ijc.30465 |
0.273 |
|
| 2005 |
Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Molecular Cancer Therapeutics. 4: 1268-1276. PMID 16093443 DOI: 10.1158/1535-7163.MCT-05-0121 |
0.273 |
|
| 2013 |
Jordheim LP, Dumontet C. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomarkers in Medicine. 7: 663-71. PMID 23905902 DOI: 10.2217/Bmm.13.48 |
0.273 |
|
| 2017 |
Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, et al. High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World Journal of Stem Cells. 9: 227-234. PMID 29321824 DOI: 10.4252/Wjsc.V9.I12.227 |
0.271 |
|
| 2009 |
Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Molecular Cancer Therapeutics. 8: 17-25. PMID 19139109 DOI: 10.1158/1535-7163.MCT-08-0986 |
0.269 |
|
| 2009 |
Dumontet C, Galia P, Leleu X, Avet-Loiseau H, Sobol H. Analysis of Familial Dysglobulinemia: a Multicenter IFM Study. Blood. 114: 4891-4891. DOI: 10.1182/Blood.V114.22.4891.4891 |
0.269 |
|
| 2008 |
Vendrell J, Ghayad S, Bieche I, Spyratos F, Dumontet C, Lidereau R, Cohen P. Candidate molecular markers associated with endocrine resistance in breast carcinoma European Journal of Cancer Supplements. 6: 118. DOI: 10.1016/S1359-6349(08)71622-7 |
0.269 |
|
| 2005 |
Sève P, Mackey JR, Isaac S, Trédan O, Souquet PJ, Pérol M, Cass C, Dumontet C. CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer Lung Cancer. 49: 363-370. PMID 15923058 DOI: 10.1016/j.lungcan.2005.04.008 |
0.268 |
|
| 2015 |
Spasevska I, Duong MN, Klein C, Dumontet C. Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies Journal of Blood Disorders and Transfusion. 6: 0. DOI: 10.4172/2155-9864.1000243 |
0.267 |
|
| 2017 |
Puy JY, Jordheim LP, Cros-Perrial E, Dumontet C, Peyrottes S, Lefebvre-Tournier I. Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1053: 101-110. PMID 28415014 DOI: 10.1016/J.Jchromb.2017.03.024 |
0.267 |
|
| 2016 |
Nguyen Van T, Hospital A, Lionne C, Jordheim LP, Dumontet C, Périgaud C, Chaloin L, Peyrottes S. Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation. Beilstein Journal of Organic Chemistry. 12: 1476-86. PMID 27559400 DOI: 10.3762/Bjoc.12.144 |
0.266 |
|
| 2012 |
Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Reis RMV, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, ... ... Dumontet C, et al. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium British Journal of Haematology. 157: 331-338. PMID 22590720 DOI: 10.1111/J.1365-2141.2012.09047.X |
0.263 |
|
| 2002 |
Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. International Journal of Cancer. Journal International Du Cancer. 97: 439-45. PMID 11802204 DOI: 10.1002/ijc.1628 |
0.263 |
|
| 2013 |
Doléans-Jordheim A, Veron JB, Fendrich O, Bergeron E, Montagut-Romans A, Wong YS, Furdui B, Freney J, Dumontet C, Boumendjel A. 3-Aryl-4-methyl-2-quinolones targeting multiresistant Staphylococcus aureus bacteria. Chemmedchem. 8: 652-7. PMID 23436688 DOI: 10.1002/Cmdc.201200551 |
0.263 |
|
| 2015 |
Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer. 22: 545-59. PMID 26099684 DOI: 10.1530/Erc-15-0029 |
0.262 |
|
| 2013 |
Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RMV, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, ... ... Dumontet C, et al. Erratum: Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: A case - Control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium (Leukemia (2012) 26 (1419-1422) DOI: 10.1038/leu.2011.352) Leukemia. 27: 1615-1616. DOI: 10.1038/Leu.2013.146 |
0.261 |
|
| 2013 |
Martino A, Sainz J, Reis RM, Moreno V, Buda G, Lesueur F, Marques H, García-Sanz R, Ríos R, Stein A, Dumontet C, Gemignani F, Maria Rossi A, Landi S, Jurado M, et al. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: A case-control study in the context of the IMMEnSE consortium Journal of Human Genetics. 58: 155-159. PMID 23303387 DOI: 10.1038/Jhg.2012.149 |
0.26 |
|
| 2014 |
Martino A, Campa D, Jurczyszyn A, MartÃnez-López J, Moreno MJ, Varkonyi J, Dumontet C, GarcÃa-Sanz R, Gemignani F, Jamroziak K, StÄ™pieÅ‚ A, Jacobsen SE, Andersen V, Jurado M, Landi S, et al. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 670-4. PMID 24521996 DOI: 10.1158/1055-9965.Epi-13-1115 |
0.259 |
|
| 2006 |
Jordheim L, Cros E, Galmarini C, Dumontet C, Bretonnet AS, Krimm I, Lancelin JM, Gagnieu MC. F-ara-AMP is a substrate of cytoplasmic 5′-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation Nucleosides, Nucleotides and Nucleic Acids. 25: 289-297. PMID 16629121 DOI: 10.1080/15257770500458027 |
0.258 |
|
| 2020 |
Sánchez-Maldonado JM, Campa D, Springer J, Badiola J, Niazi Y, Moñiz-Díez A, Hernández-Mohedo F, González-Sierra P, Ter Horst R, Macauda A, Brezina S, Cunha C, Lackner M, López-Nevot MA, Fianchi L, ... ... Dumontet C, et al. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. Blood Cancer Journal. 10: 75. PMID 32678078 DOI: 10.1038/S41408-020-00341-Y |
0.257 |
|
| 2017 |
Raza MZ, Allegrini S, Dumontet C, Jordheim LP. Functions of the multi-interacting protein KIDINS220/ARMS in cancer and other pathologies. Genes, Chromosomes & Cancer. PMID 29181864 DOI: 10.1002/Gcc.22514 |
0.256 |
|
| 2017 |
Kryza D, De Crozals G, Mathe D, Taleb J, Janier M, Chaix C, Dumontet C. G-CSF nanocarriers for stimulation of the immune system (Part II): Dose-dependent biodistribution and in vivo anti-tumor efficacy in combination with Rituximab. Bioconjugate Chemistry. PMID 29283559 DOI: 10.1021/Acs.Bioconjchem.7B00606 |
0.255 |
|
| 1999 |
Milea D, Zech C, Dumontet C, Coiffier B, Trepsat C. Transient acute myopia induced by antilymphocyte globulins Ophthalmologica. 213: 133-134. PMID 9885391 DOI: 10.1159/000027406 |
0.255 |
|
| 2018 |
Clay-Gilmour AI, Camp NJ, Wei X, Norman AD, Sinnwell JP, Demangel D, Waller RG, Dumontet C, McKay J, Offit K, Chen S, O'Brien DR, Rajkumar SV, Klein R, Kumar SK, et al. Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families Blood. 132: 4501-4501. DOI: 10.1182/Blood-2018-99-119320 |
0.255 |
|
| 2017 |
Hirz T, Matera EL, Chettab K, Jordheim LP, Mathé D, Evesque A, Esmenjaud J, Salles G, Dumontet C. Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. Oncotarget. 8: 72818-72834. PMID 29069828 DOI: 10.18632/oncotarget.20350 |
0.255 |
|
| 2004 |
Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1864-71. PMID 15143078 DOI: 10.1200/Jco.2004.06.033 |
0.255 |
|
| 2005 |
Sève P, Dumontet C. Chemoresistance in non-small cell lung cancer Current Medicinal Chemistry - Anti-Cancer Agents. 5: 73-88. PMID 15720263 DOI: 10.2174/1568011053352604 |
0.254 |
|
| 2001 |
Simon PN, Chaboud A, Darbour N, Di Pietro A, Dumontet C, Lurel F, Raynaud J, Barron D. Modulation of cancer cell multidrug resistance by an extract of Ficus citrifolia Anticancer Research. 21: 1023-1028. PMID 11396135 |
0.254 |
|
| 2010 |
Lina R, Dalle S, Mestas J, Tournebize C, Dumontet C. 69: Chronic Lymphocytic Leukemia and anti-CD20 monoclonal antibodies Bulletin Du Cancer. 97: S60. DOI: 10.1016/S0007-4551(15)31162-0 |
0.254 |
|
| 2005 |
Bretonnet AS, Jordheim LP, Dumontet C, Lancelin JM. Regulation and activity of cytosolic 5′-nucleotidase II: A bifunctional allosteric enzyme of the Haloacid Dehalogenase superfamily involved in cellular metabolism Febs Letters. 579: 3363-3368. PMID 15946667 DOI: 10.1016/J.Febslet.2005.05.014 |
0.252 |
|
| 2016 |
Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, et al. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget. 7: 2889-909. PMID 26284582 DOI: 10.18632/oncotarget.3898 |
0.252 |
|
| 2006 |
Galmarini CM, Bouchet BP, Audoynaud C, Lamblot C, Falette N, Bertholon J, Wang Q, Beghin A, Dumontet C, Puisieux A. A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. International Journal of Cancer. 119: 60-6. PMID 16432835 DOI: 10.1002/ijc.21770 |
0.251 |
|
| 2016 |
Bricard G, Cros-Perrial E, Machon C, Dumontet C, Jordheim LP. Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II. Nucleosides, Nucleotides & Nucleic Acids. 35: 604-612. PMID 27906612 DOI: 10.1080/15257770.2016.1163375 |
0.251 |
|
| 2012 |
Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, ... ... Dumontet C, et al. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: A case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium Leukemia. 26: 1419-1422. PMID 22182917 DOI: 10.1038/Leu.2011.352 |
0.25 |
|
| 2003 |
Hayette S, Tigaud I, Callet-Bauchu E, Ffrench M, Gazzo S, Wahbi K, Callanan M, Felman P, Dumontet C, Magaud JP, Rimokh R. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood. 102: 1549-50. PMID 12900351 DOI: 10.1182/Blood-2003-04-1220 |
0.25 |
|
| 2010 |
Dumontet C, Jordan MA. Microtubule-binding agents: A dynamic field of cancer therapeutics (Nature Reviews Drug Discovery (2010) 9 (790-803)) Nature Reviews Drug Discovery. 9: 897. DOI: 10.1038/Nrd3313 |
0.249 |
|
| 2018 |
Grasselly C, Denis M, Bourguignon A, Talhi N, Tourette A, Mathe D, Serre L, Jordheim LP, Dumontet C. Abstract 2723: In vivo activity of combinations of cytotoxic regimens with anti-PD1 and anti-PDL1 in various syngeneic cancer models Immunology. DOI: 10.1158/1538-7445.Am2018-2723 |
0.248 |
|
| 2019 |
Bessueille L, Briolay A, Como J, Mansouri C, Gleizes M, El JA, Buchet R, Dumontet C, Matera E, Mornet E, Millan JL, Fonta C, Magne D. Chronic recurrent multifocal osteomyelitis in children with hypophosphatasia explained by anti-inflammatory nucleotidase activity of tissue nonspecific alkaline phosphatase in mesenchymal and hematopoietic cells Bone Abstracts. DOI: 10.1530/Boneabs.7.Lb5 |
0.248 |
|
| 2006 |
Jordheim LP, Galmarini CM, Dumontet C. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells Cancer Chemotherapy and Pharmacology. 58: 547-554. PMID 16463058 DOI: 10.1007/s00280-006-0195-8 |
0.247 |
|
| 2018 |
Sauveur J, Matera EL, Chettab K, Valet P, Guitton J, Savina A, Dumontet C. Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. Oncotarget. 9: 21141-21155. PMID 29765526 DOI: 10.18632/oncotarget.24975 |
0.246 |
|
| 2009 |
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1168-76. PMID 19204205 DOI: 10.1200/Jco.2008.18.1024 |
0.244 |
|
| 1993 |
Campos L, Bastion Y, Roubi N, Felman P, Espinouse D, Dumontet C, Debost M, Tremisi JP, Coiffier B. Peripheral blood stem cells harvested after chemotherapy and GM-CSF for treatment intensification in patients with advanced lymphoproliferative diseases Leukemia. 7: 1409-1415. PMID 8103811 |
0.244 |
|
| 2012 |
Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, García-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Ríos R, Szemraj-Rogucka Z, Szemraj J, Tjønneland A, ... ... Dumontet C, et al. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma British Journal of Haematology. 158: 805-809. PMID 22823248 DOI: 10.1111/J.1365-2141.2012.09244.X |
0.243 |
|
| 2007 |
Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Hérault O, Garnache F, Garand R, Varoqueaux N, Avet-Loiseau H, Harousseau JL, Bataille R. Rituximab in CD20 positive multiple myeloma. Leukemia. 21: 835-836. PMID 17268523 DOI: 10.1038/Sj.Leu.2404558 |
0.243 |
|
| 2008 |
Hamoudeh M, Diab R, Fessi H, Dumontet C, Cuchet D. Paclitaxel-loaded microparticles for intratumoral administration via the TMT technique: Preparation, characterization, and preliminary antitumoral evaluation Drug Development and Industrial Pharmacy. 34: 698-707. PMID 18612910 DOI: 10.1080/03639040701842444 |
0.243 |
|
| 2017 |
Spasevska I, Villé J, Chettab K, Matera E, Dumontet C. Abstract 4594: Induction of apoptosis by anti-CD20 antibodies requires the induction of EGR-1 and calcium influx Immunology. 77: 4594-4594. DOI: 10.1158/1538-7445.Am2017-4594 |
0.242 |
|
| 2002 |
Galmarini CM, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E, Dumontet C. Potential mechanisms of resistance to cytarabine in AML patients Leukemia Research. 26: 621-629. PMID 12008078 DOI: 10.1016/S0145-2126(01)00184-9 |
0.241 |
|
| 2009 |
Gouy MH, Jordheim LP, Lefebvre I, Cros E, Dumontet C, Peyrottes S, Périgaud C. Special feature of mixed phosphotriester derivatives of cytarabine. Bioorganic & Medicinal Chemistry. 17: 6340-7. PMID 19674903 DOI: 10.1016/j.bmc.2009.07.038 |
0.24 |
|
| 2003 |
Galmarini CM, Voorzanger N, Falette N, Jordheim L, Cros E, Puisieux A, Dumontet C. Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine Biochemical Pharmacology. 65: 121-129. PMID 12473386 DOI: 10.1016/S0006-2952(02)01448-X |
0.24 |
|
| 2002 |
Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M. Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy Electronic Journal of Oncology. 58-64. |
0.238 |
|
| 2003 |
Galmarini CM, Clarke ML, Santos CL, Jordheim L, Perigaud C, Gosselin G, Cros E, Mackey JR, Dumontet C. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. International Journal of Cancer. Journal International Du Cancer. 107: 149-54. PMID 12925971 DOI: 10.1002/ijc.11339 |
0.237 |
|
| 2019 |
Fahed D, Chettab K, Mehlen P, Mathe D, Tourette A, Denis M, Traverse-Glehen A, Karlin L, Dumontet C. Abstract 5291: Netrin-1 expression and targeting in multiple myeloma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-5291 |
0.236 |
|
| 2005 |
Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin Du Cancer. 92: E25-30. PMID 15749640 |
0.235 |
|
| 2015 |
de Ravel MR, Alameh G, Melikian M, Mahiout Z, Emptoz-Bonneton A, Matera EL, Lomberget T, Barret R, Rocheblave L, Walchshofer N, Beltran S, El Jawad L, Mappus E, Grenot C, Pugeat M, ... Dumontet C, et al. Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells. Journal of Medicinal Chemistry. 58: 1832-45. PMID 25634041 DOI: 10.1021/Jm501676V |
0.235 |
|
| 2009 |
Michallet M, Sobh M, Le Q, Barraco F, Dumontet C, Plesa C, Chelghoum Y, Cannas G, Virelizier E, Thomas S, Praire A, Nicolini F, Troncy J. A076 Long-Term Follow-up of Multiple Myeloma Patients Treated by VELCADE Clinical Lymphoma, Myeloma & Leukemia. 9. DOI: 10.1016/S1557-9190(11)70451-6 |
0.234 |
|
| 2002 |
Dumontet C. Gemcitabine in the treatment of hematological malignancies Bulletin Du Cancer. 89. PMID 12449043 |
0.234 |
|
| 2005 |
Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, Lai R, Voloch A, Dumontet C. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Molecular Cancer Therapeutics. 4: 2001-2007. PMID 16373715 DOI: 10.1158/1535-7163.MCT-05-0244 |
0.232 |
|
| 2019 |
Dargaud Y, Fouassier M, Bordet JC, Ducastelle-Lepretre S, Dumontet C, Moreau P, Michallet M. The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis? Leukemia & Lymphoma. 1-4. PMID 30942646 DOI: 10.1080/10428194.2019.1585839 |
0.23 |
|
| 2016 |
Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw JF, Goetsch L, Bailly C, Dumontet C, Matthes T, Corvaia N, Klinguer Hamour C. A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells. Molecular Cancer Therapeutics. PMID 27297868 DOI: 10.1158/1535-7163.MCT-16-0041 |
0.23 |
|
| 2011 |
Arnaud O, Boumendjel A, Gèze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A, Payen L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. European Journal of Cancer (Oxford, England : 1990). 47: 640-8. PMID 21216589 DOI: 10.1016/j.ejca.2010.11.019 |
0.229 |
|
| 2004 |
Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clinical Cancer Research. 10: 6956-6961. PMID 15501974 DOI: 10.1158/1078-0432.CCR-04-0224 |
0.229 |
|
| 2007 |
Dalle S, Dumontet C. [Rituximab: mechanism of action and resistance]. Bulletin Du Cancer. 94: 198-202. PMID 17337389 |
0.229 |
|
| 2011 |
Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C. Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. Molecular Cancer Therapeutics. 10: 303-12. PMID 21216936 DOI: 10.1158/1535-7163.MCT-10-0568 |
0.228 |
|
| 2009 |
Beghin A, Belin S, Hage-Sleiman R, Manquat SB, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon M, Diaz J, Dumontet C. Correction: ADP Ribosylation Factor Like 2 (Arl2) Regulates Breast Tumor Aggressivity in Immunodeficient Mice Plos One. 4. DOI: 10.1371/Annotation/B0D43779-C9Aa-44Fe-A46D-71D7D2Bc4A6A |
0.226 |
|
| 2003 |
Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, Puisieux A, Jordan MA, Dumontet C. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics British Journal of Cancer. 88: 1793-1799. PMID 12771997 DOI: 10.1038/sj.bjc.6600960 |
0.226 |
|
| 2011 |
Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, Dumontet C, Puisieux A, Nicolini FE, Maguer-Satta V. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 117: 1673-6. PMID 21123820 DOI: 10.1182/blood-2009-11-254680 |
0.226 |
|
| 2009 |
Nguyen VT, Darbour N, Bayet C, Doreau A, Raad I, Phung BH, Dumontet C, Di Pietro A, Dijoux-Franca MG, Guilet D. Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla. Fitoterapia. 80: 39-42. PMID 18940238 DOI: 10.1016/j.fitote.2008.09.010 |
0.226 |
|
| 2014 |
Machon C, Jordheim LP, Puy JY, Lefebvre I, Dumontet C, Guitton J. Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry. 406: 2925-41. PMID 24633509 DOI: 10.1007/S00216-014-7711-1 |
0.226 |
|
| 2004 |
Cros E, Jordheim L, Dumontet C, Galmarini CM. Problems related to resistance to cytarabine in acute myeloid leukemia Leukemia and Lymphoma. 45: 1123-1132. PMID 15359991 DOI: 10.1080/1042819032000159861 |
0.225 |
|
| 2007 |
Sarno S, Shaw J, Spooner E, Ma J, Clark A, Dumontet C, Romanelli A. The Novel Aurora Kinase Inhibitor AS703569 Shows Potent Anti-Tumor Activity in Acute Myeloid Leukemia (AML). Blood. 110: 915-915. DOI: 10.1182/blood.v110.11.915.915 |
0.224 |
|
| 2009 |
Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. Mabs. 1: 222-9. PMID 20065642 DOI: 10.4161/mabs.1.3.8292 |
0.223 |
|
| 2017 |
Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C. Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. Plos One. 12: e0170160. PMID 28103300 DOI: 10.1371/Journal.Pone.0170160 |
0.222 |
|
| 2008 |
Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 62: 105-12. PMID 18395930 DOI: 10.1016/j.lungcan.2008.02.021 |
0.221 |
|
| 1999 |
Carles G, Braguer D, Dumontet C, Bourgarel V, Gonçalves A, Sarrazin M, Rognoni JB, Briand C. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. British Journal of Cancer. 80: 1162-8. PMID 10376967 DOI: 10.1038/sj.bjc.6690481 |
0.219 |
|
| 2007 |
Beghin A, Honore S, Messana C, Matera EL, Aim J, Burlinchon S, Braguer D, Dumontet C. ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells Experimental Cell Research. 313: 473-485. PMID 17188265 DOI: 10.1016/j.yexcr.2006.10.024 |
0.219 |
|
| 2005 |
Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, Hanson J, Young JD, Merle-Béral H, Binet JL, Cass CE, ... Dumontet C, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood. 105: 767-74. PMID 15454483 DOI: 10.1182/Blood-2004-03-1046 |
0.219 |
|
| 1996 |
Dumontet C, Roch AM, Quash G. Methionine dependence of tumor cells: Programmed cell survival? Oncology Research. 8: 469-471. PMID 9160350 |
0.218 |
|
| 2019 |
Boyle E, Deshpande S, Tytarenko R, Ashby C, Ryan K, Wang Y, Bauer M, Johnson S, Wardell C, Schinke C, Thanendrarajan S, van Rhee F, Zangari M, Facon T, Dumontet C, et al. Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e59-e60. DOI: 10.1016/J.Clml.2019.09.092 |
0.218 |
|
| 2010 |
Sève P, Reiman T, Dumontet C. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 67: 136-43. PMID 19828208 DOI: 10.1016/j.lungcan.2009.09.007 |
0.215 |
|
| 1998 |
Dumontet C, Bodin F, Michal Y. Potential interactions between antitubulin agents and temperature: Implications for modulation of multidrug resistance Clinical Cancer Research. 4: 1563-1566. PMID 9626478 |
0.215 |
|
| 2004 |
Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, Perigaud C, Dumontet C. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5614-21. PMID 15328204 DOI: 10.1158/1078-0432.CCR-04-0506 |
0.214 |
|
| 2010 |
Sève P, Dumontet C. Class III β tubulin expression in nonsmall cell lung cancer Revue Des Maladies Respiratoires. 27: 383-386. PMID 20403547 DOI: 10.1016/j.rmr.2010.03.006 |
0.214 |
|
| 2023 |
Clavero E, Sanchez-Maldonado JM, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, García-Sanz R, Tomczak W, Vogel U, Jerez A, ... ... Dumontet C, et al. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. International Journal of Molecular Sciences. 24. PMID 37239846 DOI: 10.3390/ijms24108500 |
0.213 |
|
| 2005 |
Jordheim LP, Galmarini CM, Dumontet C. Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues Bulletin Du Cancer. 92: 239-248. PMID 15820918 |
0.21 |
|
| 2009 |
Dufour JF, Pradat P, Ruivard M, Hot A, Dumontet C, Broussolle C, Trepo C, Sève P. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. European Journal of Gastroenterology & Hepatology. 21: 245-53. PMID 19279468 DOI: 10.1097/Meg.0B013E3283249908 |
0.21 |
|
| 2015 |
Duong MN, Cleret A, Matera EL, Chettab K, Mathé D, Valsesia-Wittmann S, Clémenceau B, Dumontet C. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Research : Bcr. 17: 57. PMID 25908175 DOI: 10.1186/s13058-015-0569-0 |
0.209 |
|
| 2002 |
Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia British Journal of Haematology. 117: 860-868. PMID 12060121 DOI: 10.1046/j.1365-2141.2002.03538.x |
0.208 |
|
| 2006 |
Jordheim LP, Galmarini CM, Dumontet C. Recent developments to improve the efficacy of cytotoxic nucleoside analogues Recent Patents On Anti-Cancer Drug Discovery. 1: 163-170. PMID 18221034 DOI: 10.2174/157489206777442205 |
0.207 |
|
| 2008 |
Sève P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanéchère L, Sawyer M, Dumontet C. Protein abundance of class III beta-tubulin but not Δ2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site Anticancer Research. 28: 1161-1167. PMID 18505052 |
0.207 |
|
| 2003 |
Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical Breast Cancer. 3: 341-5. PMID 12533264 DOI: 10.3816/CBC.2002.n.037 |
0.207 |
|
| 2011 |
Dumontet C. Therapeutic bispecific antibodies: Two times more powerful? Bulletin Du Cancer. 98: 1381-1382. DOI: 10.1684/Bdc.2011.1492 |
0.207 |
|
| 2014 |
Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4574-83. PMID 24987056 DOI: 10.1158/1078-0432.Ccr-14-0695 |
0.206 |
|
| 2019 |
Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, ... ... Dumontet C, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. PMID 30967618 DOI: 10.1038/S41375-019-0452-6 |
0.205 |
|
| 2010 |
Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C. Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. Bmc Cancer. 10: 135. PMID 20384997 DOI: 10.1186/1471-2407-10-135 |
0.205 |
|
| 2008 |
Honorat M, Mesnier A, Pietro AD, Lin V, Cohen P, Dumontet C, Payen L. Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells Biochemical and Biophysical Research Communications. 375: 308-314. PMID 18692485 DOI: 10.1016/j.bbrc.2008.07.149 |
0.204 |
|
| 2022 |
Nguyen KA, Conilh L, Falson P, Dumontet C, Boumendjel A. The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. European Journal of Medicinal Chemistry. 244: 114863. PMID 36334452 DOI: 10.1016/j.ejmech.2022.114863 |
0.204 |
|
| 2000 |
Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults Journal of Clinical Oncology. 18: 3643-3650. PMID 11054437 |
0.203 |
|
| 2007 |
Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 994-9. PMID 17289895 DOI: 10.1158/1078-0432.Ccr-06-1503 |
0.202 |
|
| 2013 |
Boyer-Provera E, Rossi A, Oriol L, Dumontet C, Plesa A, Berguiga L, Elezgaray J, Arneodo A, Argoul F. Wavelet-based decomposition of high resolution surface plasmon microscopy V(Z) curves at visible and near infrared wavelengths Optics Express. 21: 7456-7477. PMID 23546129 DOI: 10.1364/Oe.21.007456 |
0.202 |
|
| 1999 |
Dumontet C, Bauchu EC, Fabianowska K, Lepoivre M, Wyczechowska D, Bodin F, Rolland MO. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562 Advances in Experimental Medicine and Biology. 457: 571-577. PMID 10500836 |
0.199 |
|
| 2017 |
Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, et al. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML. Leukemia Research. 56: 21-28. PMID 28167452 DOI: 10.1016/j.leukres.2017.01.012 |
0.198 |
|
| 2004 |
Decouvelaere AV, Morschhauser F, Copin M, Dumontet CM. PKC beta II Expression in Lymphoid Malignancies. Blood. 104: 4539-4539. DOI: 10.1182/blood.v104.11.4539.4539 |
0.198 |
|
| 2019 |
Delort L, Bougaret L, Cholet J, Vermerie M, Billard H, Decombat C, Bourgne C, Berger M, Dumontet C, Caldefie-Chezet F. Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin. Nutrients. 11. PMID 31756890 DOI: 10.3390/nu11122839 |
0.197 |
|
| 2020 |
Eva-Laure M, Julien F, Estelle B, Emeline P, Zineb B, Chettab A, Petter Jordheim L, Dumontet C. Enhanced Sensitivity of Idelalisib and Ibrutinib-Resistant Cell Lines to Anti-CD38 Antibodies Journal of Cancer Science and Clinical Therapeutics. 4. DOI: 10.26502/jcsct.5079052 |
0.197 |
|
| 2008 |
Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia British Journal of Haematology. 143: 54-59. PMID 18710390 DOI: 10.1111/j.1365-2141.2008.07309.x |
0.196 |
|
| 2004 |
Lee S, Roy F, Galmarini CM, Accardi R, Michelon J, Viller A, Cros E, Dumontet C, Sylla BS. Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene. 23: 2287-97. PMID 14730347 DOI: 10.1038/sj.onc.1207385 |
0.193 |
|
| 2016 |
Hirz T, Dumontet C. Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents. Journal of Visualized Experiments : Jove. PMID 27078837 DOI: 10.3791/53846 |
0.193 |
|
| 2007 |
Moulin M, Dumontet C, Arrigo AP. Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia Cancer Letters. 250: 117-127. PMID 17141951 DOI: 10.1016/j.canlet.2006.10.019 |
0.193 |
|
| 2008 |
Dumontet C, Galia P, Sobol H. Research of genetic factors predisposing to dysglobulinemia Ejc Supplements. 6: 202. DOI: 10.1016/S1359-6349(08)71893-7 |
0.192 |
|
| 2010 |
Dumontet C. Is T351I mutation about to be conquered? Bulletin Du Cancer. 97: 611. DOI: 10.1684/Bdc.2010.1103 |
0.191 |
|
| 2002 |
Boumendjel A, Di Pietro A, Dumontet C, Barron D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance Medicinal Research Reviews. 22: 512-529. PMID 12210557 DOI: 10.1002/med.10015 |
0.191 |
|
| 2010 |
Reslan L, Mestas JL, Herveau S, Béra JC, Dumontet C. Transfection of cells in suspension by ultrasound cavitation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 142: 251-8. PMID 19896995 DOI: 10.1016/j.jconrel.2009.10.029 |
0.19 |
|
| 2002 |
Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment Lancet Oncology. 3: 415-424. PMID 12142171 DOI: 10.1016/S1470-2045(02)00788-X |
0.189 |
|
| 2021 |
Fahed D, Chettab A, Mathe D, Denis M, Traverse-Glehen A, Karlin L, Perrial E, Dumontet C. Netrin-1 expression and targeting in multiple myeloma. Leukemia & Lymphoma. 1-9. PMID 34585999 DOI: 10.1080/10428194.2021.1984459 |
0.189 |
|
| 1988 |
Dumontet C, Dodon MD, Gazzolo L, Gerlier D. Human T-cell leukemia virus type I-induced proliferation of human thymocytes requires the presence of a comitogen Cellular Immunology. 112: 391-401. PMID 2833357 DOI: 10.1016/0008-8749(88)90308-5 |
0.188 |
|
| 2014 |
Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguet F, Michallet M, Dumontet C, Recher C, Thomas X. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia & Lymphoma. 55: 855-62. PMID 23786457 DOI: 10.3109/10428194.2013.813504 |
0.188 |
|
| 2003 |
Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). The Hematology Journal : the Official Journal of the European Haematology Association. 3: 185-92. PMID 12189564 DOI: 10.1038/SJ.THJ.6200175 |
0.188 |
|
| 2017 |
Bricard G, Cadassou O, Cassagnes LE, Cros-Perrial E, Payen-Gay L, Puy JY, Lefebvre-Tournier I, Tozzi MG, Dumontet C, Jordheim LP. The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget. PMID 28679870 DOI: 10.18632/oncotarget.18653 |
0.188 |
|
| 2008 |
Dumontet C. [Optimising therapy in patients with haematological malignancies]. Bulletin Du Cancer. 95: 959-62. PMID 19004726 DOI: 10.1684/bdc.2008.0718 |
0.186 |
|
| 2007 |
Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C. Heterogeneity of protein kinase C β2 expression in lymphoid malignancies Histopathology. 50: 561-566. PMID 17394491 DOI: 10.1111/j.1365-2559.2007.02666.x |
0.186 |
|
| 2017 |
Duong MN, Geneste A, Fallone F, Li X, Dumontet C, Muller C. The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget. 8: 57622-57641. PMID 28915700 DOI: 10.18632/oncotarget.18038 |
0.185 |
|
| 2017 |
Duong MN, Geneste A, Fallone F, Li X, Dumontet C, Muller C. The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget. PMID 28589909 DOI: 10.18632/oncotarget.18038 |
0.185 |
|
| 2008 |
Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: A single-institution experience Cancer. 112: 572-580. PMID 18085638 DOI: 10.1002/cncr.23219 |
0.185 |
|
| 2009 |
Corea G, Di Pietro A, Dumontet C, Fattorusso E, Lanzotti V. Jatrophane diterpenes from Euphorbia spp. as modulators of multidrug resistance in cancer therapy Phytochemistry Reviews. 8: 431-447. DOI: 10.1007/s11101-009-9126-8 |
0.184 |
|
| 1997 |
Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, Felman P, Coiffier B. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: Analysis of 108 patients Journal of Clinical Oncology. 15: 1624-1630. PMID 9193362 |
0.184 |
|
| 2018 |
Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Frontiers in Immunology. 9: 2100. PMID 30356816 DOI: 10.3389/fimmu.2018.02100 |
0.184 |
|
| 1998 |
Dumontet C, Ketterer N, Espinouse D, Neidhardt EM, Moullet I, Thieblemont C, Salles G, Coiffier B. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma Bone Marrow Transplantation. 21: 1037-1041. PMID 9632278 |
0.182 |
|
| 2000 |
Dumontet C. Mechanisms of action and resistance to tubulin-binding agents Expert Opinion On Investigational Drugs. 9: 779-788. PMID 11060709 |
0.182 |
|
| 2007 |
Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene. 26: 4656-67. PMID 17297453 DOI: 10.1038/sj.onc.1210269 |
0.181 |
|
| 1992 |
Bastion Y, Felman P, Dumontet C, Espinouse D, Coiffier B. Intensive radio-chemotherapy with peripheral blood stem cell transplantation in young patients with chronic lymphocytic leukemia Bone Marrow Transplantation. 10: 467-468. PMID 1464012 |
0.181 |
|
| 2003 |
Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine British Journal of Haematology. 122: 53-60. PMID 12823345 DOI: 10.1046/j.1365-2141.2003.04386.x |
0.181 |
|
| 2009 |
Belin S, Beghin A, Solano-Gonzàlez E, Bezin L, Brunet-Manquat S, Textoris J, Prats AC, Mertani HC, Dumontet C, Diaz JJ. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. Plos One. 4: e7147. PMID 19779612 DOI: 10.1371/Journal.Pone.0007147 |
0.181 |
|
| 2001 |
Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies Leukemia. 15: 875-890. PMID 11417472 DOI: 10.1038/sj.leu.2402114 |
0.18 |
|
| 2000 |
Dumontet C. Predictive factors of chemotherapy resistance in patients with breast cancer Annales De Pathologie. 20. PMID 11261312 |
0.18 |
|
| 2011 |
Esteves IT, Dumontet C, Herveau S, Reslan L, Brune F, Van Overtvelt L, Salcedo M, Fournès B. LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models Blood. 118: 1660-1660. DOI: 10.1182/BLOOD.V118.21.1660.1660 |
0.179 |
|
| 2023 |
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nature Reviews. Drug Discovery. PMID 37308581 DOI: 10.1038/s41573-023-00709-2 |
0.178 |
|
| 2007 |
Diab R, Degobert G, Hamoudeh M, Dumontet C, Fessi H. Nucleoside analogue delivery systems in cancer therapy. Expert Opinion On Drug Delivery. 4: 513-31. PMID 17880274 DOI: 10.1517/17425247.4.5.513 |
0.178 |
|
| 2000 |
Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed Blood. 95: 802-806. PMID 10648389 |
0.176 |
|
| 2022 |
Denis M, Grasselly C, Choffour PA, Wierinckx A, Mathe D, Chettab K, Tourette A, Talhi N, Bourguignon A, Birzele F, Kress E, Jordheim LP, Klein C, Matera EL, Dumontet C. IN VIVO SYNGENEIC TUMOR MODELS WITH ACQUIRED RESISTANCE TO ANTI-PD-1/PD-L1 THERAPIES. Cancer Immunology Research. PMID 35679518 DOI: 10.1158/2326-6066.CIR-21-0802 |
0.176 |
|
| 2021 |
Giaccherini M, Macauda A, Orciuolo E, Rymko M, Gruenpeter K, Dumontet C, Raźny M, Moreno V, Buda G, Beider K, Varkonyi J, Avet-Loiseau H, Martinez-Lopez J, Marques H, Watek M, et al. Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal. 11: 74. PMID 33854038 DOI: 10.1038/s41408-021-00462-y |
0.175 |
|
| 2003 |
Galmarini CM, Jordheim L, Dumontet C. Pyrimidine nucleoside analogs in cancer treatment Expert Review of Anticancer Therapy. 3: 717-728. PMID 14599094 |
0.175 |
|
| 2017 |
Chettab K, Mestas JL, Lafond M, Saadna DE, Lafon C, Dumontet C. Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents. Molecular Pharmaceutics. PMID 28107023 DOI: 10.1021/acs.molpharmaceut.6b00880 |
0.175 |
|
| 2003 |
Gamberale R, Galmarini CM, Fernández-Calotti P, Jordheim L, Sánchez-Avalos J, Dumontet C, Geffner J, Giordano M. In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine Biochemical Pharmacology. 66: 2185-2191. PMID 14609743 DOI: 10.1016/j.bcp.2003.07.008 |
0.174 |
|
| 2021 |
Raza MZ, Cadassou O, Dumontet C, Cros-Perrial E, Jordheim LP. CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells. Biochimica Et Biophysica Acta. General Subjects. 1865: 129842. PMID 33434633 DOI: 10.1016/j.bbagen.2021.129842 |
0.173 |
|
| 2015 |
Marton Z, Guillon R, Krimm I, Preeti, Rahimova R, Egron D, Jordheim LP, Aghajari N, Dumontet C, Périgaud C, Lionne C, Peyrottes S, Chaloin L. Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach. Journal of Medicinal Chemistry. 58: 9680-96. PMID 26599519 DOI: 10.1021/acs.jmedchem.5b01616 |
0.172 |
|
| 2007 |
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, ... ... Dumontet C, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome Blood. 109: 3489-3495. PMID 17209057 DOI: 10.1182/blood-2006-08-040410 |
0.171 |
|
| 2003 |
Appendino G, Porta CD, Conseil G, Sterner O, Mercalli E, Dumontet C, Di Pietro A. A new P-glycoprotein inhibitor from the caper spurge (Euphorbia lathyris) Journal of Natural Products. 66: 140-142. PMID 12542364 DOI: 10.1021/np0203537 |
0.171 |
|
| 2021 |
Conilh L, Fournet G, Fourmaux E, Murcia A, Matera EL, Joseph B, Dumontet C, Viricel W. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel, Switzerland). 14. PMID 33803327 DOI: 10.3390/ph14030247 |
0.17 |
|
| 2020 |
Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel, Switzerland). 13. PMID 32937862 DOI: 10.3390/ph13090245 |
0.169 |
|
| 2009 |
Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. Journal of Cellular Physiology. 221: 505-13. PMID 19650075 DOI: 10.1002/Jcp.21870 |
0.169 |
|
| 2021 |
Cadassou O, Forey P, Machon C, Petrotto E, Chettab K, Tozzi MG, Guitton J, Dumontet C, Cros-Perrial E, Jordheim LP. Transcriptional and Metabolic Investigation in 5'-Nucleotidase Deficient Cancer Cell Lines. Cells. 10. PMID 34831141 DOI: 10.3390/cells10112918 |
0.169 |
|
| 2019 |
Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, ... ... Dumontet C, et al. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia & Lymphoma. 1-9. PMID 30633655 DOI: 10.1080/10428194.2018.1551536 |
0.167 |
|
| 2021 |
Macauda A, Piredda C, Clay-Gilmour AI, Sainz J, Buda G, Markiewicz M, Barington T, Ziv E, Hildebrandt MAT, Belachew AA, Varkonyi J, Prejzner W, Druzd-Sitek A, Spinelli J, Andersen NF, ... ... Dumontet C, et al. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer. PMID 33675538 DOI: 10.1002/ijc.33547 |
0.167 |
|
| 2013 |
Jordheim LP, Marton Z, Rhimi M, Cros-Perrial E, Lionne C, Peyrottes S, Dumontet C, Aghajari N, Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. Biochemical Pharmacology. 85: 497-506. PMID 23220537 DOI: 10.1016/j.bcp.2012.11.024 |
0.166 |
|
| 2008 |
Boumendjel A, Boccard J, Carrupt PA, Nicolle E, Blanc M, Geze A, Choisnard L, Wouessidjewe D, Matera EL, Dumontet C. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. Journal of Medicinal Chemistry. 51: 2307-10. PMID 18293907 DOI: 10.1021/jm0708331 |
0.166 |
|
| 2009 |
Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motility and the Cytoskeleton. 66: 378-88. PMID 19466750 DOI: 10.1002/cm.20377 |
0.166 |
|
| 2004 |
Galmarini CM, Cros E, Graham K, Thomas X, Mackey JR, Dumontet C. 5′-(3′)-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine Haematologica. 89: 617-619. PMID 15136231 |
0.165 |
|
| 2022 |
Dumontet C. Targetting glutaminase to starve lymphoma cells. Haematologica. PMID 36453109 DOI: 10.3324/haematol.2022.282348 |
0.165 |
|
| 2006 |
Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Agha IY, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood. 108: 3289-3294. PMID 16873668 DOI: 10.1182/blood-2006-05-022962 |
0.164 |
|
| 2003 |
Galmarini CM, Jordheim L, Dumontet C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies Leukemia and Lymphoma. 44: 1105-1111. PMID 12916861 DOI: 10.1080/1042819031000077142 |
0.164 |
|
| 1999 |
Ketterer N, Sonet A, Dumontet C, Moullet I, Thieblemont C, Espinouse D, Bouafia F, Coiffier B, Salles G. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: Analysis of 300 cases in a single institution Bone Marrow Transplantation. 23: 1309-1315. PMID 10414921 |
0.163 |
|
| 2019 |
Lehuédé C, Li X, Dauvillier S, Vaysse C, Franchet C, Clement E, Esteve D, Longué M, Chaltiel L, Le Gonidec S, Lazar I, Geneste A, Dumontet C, Valet P, Nieto L, et al. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). Breast Cancer Research : Bcr. 21: 7. PMID 30654824 DOI: 10.1186/s13058-018-1088-6 |
0.163 |
|
| 2021 |
Barret JM, Nicolas A, Jarry A, Dubreuil O, Meseure D, Passat T, Perrial E, Deleine C, Champenois G, Gaillard S, Duchalais E, Ray-Coquard I, Lahmar M, Dumontet C, Bennouna J, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology. 10. PMID 33917111 DOI: 10.3390/biology10040305 |
0.163 |
|
| 2020 |
Cadassou O, Raza MZ, Machon C, Gudefin L, Armanet C, Chettab K, Guitton J, Tozzi MG, Dumontet C, Cros-Perrial E, Jordheim LP. Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation. Cellular Oncology (Dordrecht). PMID 32970317 DOI: 10.1007/s13402-020-00558-w |
0.163 |
|
| 2004 |
Hadjeri M, Peiller EL, Beney C, Deka N, Lawson MA, Dumontet C, Boumendjel A. Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones Journal of Medicinal Chemistry. 47: 4964-4970. PMID 15369401 DOI: 10.1021/jm049876x |
0.162 |
|
| 2009 |
Hébrard C, Dumontet C, Jordheim LP. Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues Cancer Gene Therapy. 16: 541-550. PMID 19343063 DOI: 10.1038/cgt.2009.25 |
0.162 |
|
| 2022 |
Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczyńska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, ... ... Dumontet C, et al. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. International Journal of Cancer. PMID 36082445 DOI: 10.1002/ijc.34278 |
0.162 |
|
| 2015 |
Cividini F, Tozzi MG, Galli A, Pesi R, Camici M, Dumontet C, Jordheim LP, Allegrini S. Cytosolic 5'-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf. Plos One. 10: e0121525. PMID 25811392 DOI: 10.1371/journal.pone.0121525 |
0.162 |
|
| 2012 |
Zeinyeh W, Mahiout Z, Radix S, Lomberget T, Dumoulin A, Barret R, Grenot C, Rocheblave L, Matera EL, Dumontet C, Walchshofer N. Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: design, synthesis, characterization and biological evaluation. Steroids. 77: 1177-91. PMID 22868178 DOI: 10.1016/j.steroids.2012.07.010 |
0.161 |
|
| 2020 |
Spasevska I, Matera EL, Chettab K, Ville J, Potier-Cartereau M, Jordheim LP, Thieblemont C, Sahin D, Klein C, Dumontet C. Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction. Molecular Cancer Therapeutics. PMID 32847969 DOI: 10.1158/1535-7163.MCT-19-0839 |
0.159 |
|
| 2017 |
Spasevska I, Ayoub AT, Winter P, Preto J, Wong GK, Dumontet C, Tuszynski JA. Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin. International Journal of Molecular Sciences. 18. PMID 28767055 DOI: 10.3390/Ijms18081676 |
0.159 |
|
| 2016 |
Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, Walzer T, Dumontet C. Alteration of Natural Killer cell phenotype and function in obese individuals. Clinical Immunology (Orlando, Fla.). PMID 26794911 DOI: 10.1016/j.clim.2016.01.007 |
0.159 |
|
| 2013 |
Tagoug I, Plesa A, Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. European Journal of Pharmacology. 706: 11-6. PMID 23458070 DOI: 10.1016/j.ejphar.2013.02.002 |
0.158 |
|
| 2022 |
Harou O, Cros-Perrial E, Alix E, Callet-Bauchu E, Bertheau C, Dumontet C, Devouassoux-Shisheboran M, Jordheim LP. Variability in CD39 and CD73 protein levels in uveal melanoma patients. Nucleosides, Nucleotides & Nucleic Acids. 1-10. PMID 35199627 DOI: 10.1080/15257770.2022.2032738 |
0.158 |
|
| 2015 |
Chettab K, Roux S, Mathé D, Cros-Perrial E, Lafond M, Lafon C, Dumontet C, Mestas JL. Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. Plos One. 10: e0134247. PMID 26274324 DOI: 10.1371/journal.pone.0134247 |
0.158 |
|
| 2014 |
Meurillon M, Marton Z, Hospital A, Jordheim LP, Béjaud J, Lionne C, Dumontet C, Périgaud C, Chaloin L, Peyrottes S. Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies. European Journal of Medicinal Chemistry. 77: 18-37. PMID 24607586 DOI: 10.1016/j.ejmech.2014.02.055 |
0.158 |
|
| 2021 |
Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications. 12: 293. PMID 33436579 DOI: 10.1038/s41467-020-20524-2 |
0.156 |
|
| 1992 |
Dumontet C, Bastion Y, Felman P, Ffrench M, Blanc M, Peaud PY, Bryon PA, Coiffier B. Prognostic factors, late relapse and outcome of patients with aggressive malignant lymphoma: Long-term results of the LNH-80 protocol Bulletin Du Cancer. 79: 979-989. PMID 1284041 |
0.156 |
|
| 1987 |
Dumontet C. Use of monoclonal antibodies in the treatment of cancer Presse Medicale. 16: 2055-2058. PMID 2963270 |
0.155 |
|
| 2001 |
Comte G, Daskiewicz JB, Bayet C, Conseil G, Viornery-Vanier A, Dumontet C, Di Pietro A, Barron D. C-isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance Journal of Medicinal Chemistry. 44: 763-768. PMID 11262086 DOI: 10.1021/jm991128y |
0.155 |
|
| 2010 |
Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3988-97. PMID 20576719 DOI: 10.1158/1078-0432.CCR-10-0079 |
0.155 |
|
| 2005 |
Galmarini CM, Cros E, Thomas X, Jordheim L, Dumontet C. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia Haematologica. 90: 1699-1701. PMID 16330448 |
0.155 |
|
| 2013 |
Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Reviews. Drug Discovery. 12: 447-64. PMID 23722347 DOI: 10.1038/nrd4010 |
0.154 |
|
| 2008 |
Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53 Drug Metabolism and Disposition. 36: 2419-2423. PMID 18775979 DOI: 10.1124/dmd.108.023184 |
0.153 |
|
| 2015 |
Mestas JL, Chettab K, Roux S, Prieur F, Lafond M, Dumontet C, Lafon C. Development of a confocal ultrasound device using an inertial cavitation control for transfection in-vitro Journal of Physics: Conference Series. 656. DOI: 10.1088/1742-6596/656/1/012003 |
0.152 |
|
| 2007 |
Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma. 48: 708-15. PMID 17454628 DOI: 10.1080/10428190701190169 |
0.152 |
|
| 1994 |
Dumontet C, Rebbaa A, Bienvenu J, Portoukalian J. Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides Cancer Immunology Immunotherapy. 38: 311-316. PMID 8162613 DOI: 10.1007/BF01525509 |
0.152 |
|
| 2008 |
Doléans-Jordheim A, Michalet S, Bergeron E, Boisset S, Souard F, Dumontet C, Dijoux-Franca MG, Freney J. [Efflux pumps: their role in Staphylococcus aureus antibiotic resistance]. Annales De Biologie Clinique. 66: 499-508. PMID 18957338 DOI: 10.1684/abc.2008.0266 |
0.151 |
|
| 1991 |
Dumontet C, Portoukalian J. Gangliosides and cancer Bulletin Du Cancer. 78: 789-799. PMID 1751830 |
0.151 |
|
| 2003 |
Hequet O, Salles G, Ketterer N, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Bouafia F, Coiffier B. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation Bone Marrow Transplantation. 32: 89-95. PMID 12815483 DOI: 10.1038/sj.bmt.1704073 |
0.15 |
|
| 2021 |
Ciniero G, Elmenoufy AH, Gentile F, Weinfeld M, Deriu MA, West FG, Tuszynski JA, Dumontet C, Cros-Perrial E, Jordheim LP. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. Cancer Chemotherapy and Pharmacology. PMID 33399940 DOI: 10.1007/s00280-020-04213-x |
0.148 |
|
| 2007 |
Jordheim LP, Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues Biochimica Et Biophysica Acta - Reviews On Cancer. 1776: 138-159. PMID 17881132 DOI: 10.1016/j.bbcan.2007.07.004 |
0.147 |
|
| 1995 |
Moullet I, Salles G, Dumontet C, Bastion Y, Morel D, Felman P, Coiffier B. Sever immune thombocytopenic purpura and haemolytic anaemia in a hairy-cell leukaemia patient. European Journal of Haematology. 54: 127-9. PMID 7698298 |
0.147 |
|
| 2010 |
Zeinyeh W, Alameh G, Radix S, Grenot C, Dumontet C, Walchshofer N. Design, synthesis and evaluation of progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. Bioorganic & Medicinal Chemistry Letters. 20: 3165-8. PMID 20399647 DOI: 10.1016/j.bmcl.2010.03.085 |
0.146 |
|
| 2017 |
Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S. Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al. Pigment Cell & Melanoma Research. PMID 28627072 DOI: 10.1111/pcmr.12606 |
0.146 |
|
| 1998 |
Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, Coiffier B, Salles G. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients British Journal of Cancer. 77: 2357-2362. PMID 9649158 |
0.146 |
|
| 2004 |
Corea G, Fattorusso E, Lanzotti V, Motti R, Simon PN, Dumontet C, Di Pietro A. Structure-activity relationships for euphocharacins A-L, a new series of jatrophane diterpenes, as inhibitors of cancer cell P-glycoprotein. Planta Medica. 70: 657-65. PMID 15254859 DOI: 10.1055/s-2004-827191 |
0.145 |
|
| 2023 |
Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. Journal of Hematology & Oncology. 16: 3. PMID 36650546 DOI: 10.1186/s13045-022-01397-y |
0.145 |
|
| 2021 |
Domenech C, Plesa A, Tourette A, Bertrand Y, Dony A, Dumontet C, Cros-Perrial E, Jordheim LP. Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia. Leukemia & Lymphoma. 1-6. PMID 34661502 DOI: 10.1080/10428194.2021.1992616 |
0.144 |
|
| 2009 |
Vispé S, DeVries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Molecular Cancer Therapeutics. 8: 2780-90. PMID 19808979 DOI: 10.1158/1535-7163.Mct-09-0549 |
0.144 |
|
| 2015 |
Duong MN, Matera EL, Mathé D, Evesque A, Valsesia-Wittmann S, Clémenceau B, Dumontet C. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. Mabs. 7: 192-8. PMID 25523586 DOI: 10.4161/19420862.2015.989020 |
0.143 |
|
| 2013 |
Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P, Colombel M. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. The Prostate. 73: 1738-46. PMID 24115186 DOI: 10.1002/pros.22689 |
0.143 |
|
| 2010 |
Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews. Drug Discovery. 9: 790-803. PMID 20885410 DOI: 10.1038/Nrd3253 |
0.142 |
|
| 1992 |
Dumontet C, Biron F, Boibieux A, Allaouchiche B, Peyramond D. Chemotherapy for human immunodeficiency virus infection. Current status and perspectives Revue De Medecine Interne. 13: 460-464. PMID 1344931 |
0.141 |
|
| 2019 |
Beck A, Dumontet C, Joubert N. [Antibody-drug conjugates in oncology. Recent success of an ancient concept]. Medecine Sciences : M/S. 35: 1034-1042. PMID 31903915 DOI: 10.1051/medsci/2019227 |
0.141 |
|
| 2000 |
Duhaut P, Bosshard S, Dumontet C. Giant cell arteritis and polymyalgia rheumatica: Role of viral infections Clinical and Experimental Rheumatology. 18. PMID 10948753 |
0.141 |
|
| 1995 |
Rieux C, Bastion Y, Bazin M, Dumontet C, Coiffier B, Felman P, Bryon PA. Effectiveness of 2-chlorodeoxyadenosine in nodal and extra haematopoietic localizations in hairy cell leukaemia [2] European Journal of Haematology. 55: 133-135. PMID 7628589 |
0.14 |
|
| 2019 |
Beck A, Dumontet C, Joubert N. [Antibody-drug conjugates in oncology. New strategies in development]. Medecine Sciences : M/S. 35: 1043-1053. PMID 31903916 DOI: 10.1051/medsci/2019228 |
0.139 |
|
| 2020 |
Forey P, Cros-Perrial E, Dumontet C, Jordheim LP. Targeting the nucleotide metabolism proteins of the NUDIX family and SAMHD1 in cancer. Current Medicinal Chemistry. PMID 33238840 DOI: 10.2174/0929867328666201125120422 |
0.139 |
|
| 2010 |
Egevad L, Valdman A, Wiklund NP, Sève P, Dumontet C. Beta-tubulin III expression in prostate cancer. Scandinavian Journal of Urology and Nephrology. 44: 371-7. PMID 20831453 DOI: 10.3109/00365599.2010.515612 |
0.137 |
|
| 2020 |
Denis M, Duruisseaux M, Brevet M, Dumontet C. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? Frontiers in Immunology. 11: 492. PMID 32265935 DOI: 10.3389/fimmu.2020.00492 |
0.137 |
|
| 2012 |
Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investigational New Drugs. 30: 1121-31. PMID 21519855 DOI: 10.1007/s10637-011-9670-0 |
0.137 |
|
| 2010 |
Cohen S, Jordheim LP, Megherbi M, Dumontet C, Guitton J. Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 1912-28. PMID 20558114 DOI: 10.1016/j.jchromb.2010.05.016 |
0.136 |
|
| 2016 |
Magrangeas F, Kuiper R, Avet-Loiseau H, Gourraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Der Sarkissian H, Attal M, Munshi NC, Sonneveld P, Dumontet C, Moreau P, et al. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27060151 DOI: 10.1158/1078-0432.CCR-15-3163 |
0.136 |
|
| 1996 |
Allaouchiche B, Jaumain H, Dumontet C, Motin J. Early diagnosis of ventilator-associated pneumonia: Is it possible to define a cutoff value of infected cells in BAL fluid? Chest. 110: 1558-1565. PMID 8989077 |
0.135 |
|
| 2012 |
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, ... ... Dumontet C, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 366: 1782-91. PMID 22571202 DOI: 10.1056/NEJMoa1114138 |
0.135 |
|
| 2015 |
Pertesi M, Galia P, Nazaret N, Vallée M, Garderet L, Leleu X, Avet-Loiseau H, Foll M, Byrnes G, Lachuer J, McKay JD, Dumontet C. Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. Plos One. 10: e0136505. PMID 26352266 DOI: 10.1371/Journal.Pone.0136505 |
0.134 |
|
| 2006 |
Plesa A, Ciuperca G, Louvet V, Pujo-Menjouet L, Génieys S, Dumontet C, Thomas X, Volpert V. Diagnostics of the AML with immunophenotypical data Mathematical Modelling of Natural Phenomena. 1: 104-123. DOI: 10.1051/mmnp:2008006 |
0.134 |
|
| 2023 |
Blangero F, Robert M, Andraud T, Dumontet C, Vidal H, Eljaafari A. Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation. Cancers. 15. PMID 37296927 DOI: 10.3390/cancers15112963 |
0.133 |
|
| 2018 |
Dumontet C, Couray-Targe S, Teisseire M, Karlin L, Maucort-Boulch D. Real life management of patients hospitalized with multiple myeloma in France. Plos One. 13: e0196596. PMID 29715281 DOI: 10.1371/journal.pone.0196596 |
0.133 |
|
| 2020 |
Melaiu O, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, GrzĄŚko N, Moreno V, Jurczyszyn A, Jerez A, Watek M, Varkonyi J, ... ... Dumontet C, et al. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer. PMID 33152124 DOI: 10.1002/ijc.33377 |
0.133 |
|
| 1992 |
Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia Annals of Oncology. 3: 171-172. PMID 1606091 |
0.133 |
|
| 1995 |
Bastion Y, Campos L, Roubi N, Bienvenu J, Felman P, Dumontet C, Coiffier B. IL-3 increases marrow and peripheral erythroid precursors in chronic pure red cell aplasia presenting in childhood British Journal of Haematology. 89: 413-416. PMID 7873394 |
0.133 |
|
| 1995 |
Quash G, Roch AM, Chantepie J, Michal Y, Fournet G, Dumontet C. Methional derived from 4-methylthio-2-oxobutanoate is a cellular mediator of apoptosis in BAF3 lymphoid cells Biochemical Journal. 305: 1017-1025. PMID 7848263 |
0.132 |
|
| 2004 |
Corea G, Fattorusso E, Lanzotti V, Motti R, Simon PN, Dumontet C, Di Pietro A. Jatrophane diterpenes as modulators of multidrug resistance. Advances of structure-activity relationships and discovery of the potent lead pepluanin A. Journal of Medicinal Chemistry. 47: 988-92. PMID 14761200 DOI: 10.1021/jm030951y |
0.132 |
|
| 2002 |
Dumontet C, Mounier N, Munck JN, Bosly A, Morschauser F, Simon D, Marit G, Casasnovas O, Reman O, Molina T, Reyes F, Coiffier B. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. British Journal of Haematology. 118: 210-7. PMID 12100150 DOI: 10.1046/j.1365-2141.2002.03565.x |
0.131 |
|
| 2020 |
Delort L, Cholet J, Decombat C, Vermerie M, Dumontet C, Castelli FA, Fenaille F, Auxenfans C, Rossary A, Caldefie-Chezet F. The Adipose Microenvironment Dysregulates the Mammary Myoepithelial Cells and Could Participate to the Progression of Breast Cancer. Frontiers in Cell and Developmental Biology. 8: 571948. PMID 33505957 DOI: 10.3389/fcell.2020.571948 |
0.131 |
|
| 2004 |
Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A. Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorganic & Medicinal Chemistry. 11: 5221-7. PMID 14604686 DOI: 10.1016/j.bmc.2003.08.013 |
0.131 |
|
| 2008 |
Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, Dumontet C. Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. Blood. 112: 1585-1585. DOI: 10.1182/blood.v112.11.1585.1585 |
0.131 |
|
| 2018 |
Dumontet C, Beck G, Gardebien F, Haudecoeur R, Mathé D, Matera EL, Tourette A, Mattei E, Esmenjaud J, Boyère C, Nurisso A, Peuchmaur M, Pérès B, Bouchaud G, Magnan A, et al. Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models. European Journal of Medicinal Chemistry. 158: 405-413. PMID 30237123 DOI: 10.1016/j.ejmech.2018.09.033 |
0.13 |
|
| 2002 |
Hequet O, Salles G, Espinousse D, Dumontet C, Bouafia F, Thieblemont C, Revesz D, Coiffier B. Multifocal progressive leukoencephalopathy occurring after refractory anemia and multiple infectious disorders consecutive to severe lymphopenia Annals of Hematology. 81: 340-342. PMID 12107566 DOI: 10.1007/s00277-002-0458-3 |
0.13 |
|
| 2012 |
Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. Plos One. 7: e51329. PMID 23272099 DOI: 10.1371/Journal.Pone.0051329 |
0.129 |
|
| 2009 |
Saussede-Aim J, Matera EL, Herveau S, Rouault JP, Ferlini C, Dumontet C. Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site. Anticancer Research. 29: 3003-9. PMID 19661308 |
0.128 |
|
| 2024 |
Gouez M, Rébillard A, Thomas A, Beaumel S, Matera EL, Gouraud E, Orfila L, Martin B, Pérol O, Chaveroux C, Chirico EN, Dumontet C, Fervers B, Pialoux V. Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice. Frontiers in Immunology. 15: 1368550. PMID 38426110 DOI: 10.3389/fimmu.2024.1368550 |
0.127 |
|
| 2003 |
Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A. Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. Journal of Medicinal Chemistry. 46: 3395-402. PMID 12852769 DOI: 10.1021/jm030787e |
0.126 |
|
| 2014 |
Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leukemia & Lymphoma. 55: 188-90. PMID 23537278 DOI: 10.3109/10428194.2013.788175 |
0.124 |
|
| 2012 |
Pauwels PJ, Dumontet C, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B, Teicher B. 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. Mabs. 4: 434-44. PMID 22684281 DOI: 10.4161/mabs.20869 |
0.123 |
|
| 2009 |
Cohen S, Megherbi M, Jordheim LP, Lefebvre I, Perigaud C, Dumontet C, Guitton J. Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3831-40. PMID 19805008 DOI: 10.1016/j.jchromb.2009.09.030 |
0.123 |
|
| 2009 |
Honorat M, Dumontet C, Payen L. Multidrug Resistance-Associated Protein (MRP/ABCC Proteins) Abc Transporters and Multidrug Resistance. 47-81. DOI: 10.1002/9780470495131.ch2 |
0.123 |
|
| 2018 |
Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, ... ... Dumontet C, et al. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. Plos Genetics. 14: e1007111. PMID 29389935 DOI: 10.1371/Journal.Pgen.1007111 |
0.122 |
|
| 2009 |
Carli D, Honorat M, Cohen S, Megherbi M, Vignal B, Dumontet C, Payen L, Guitton J. Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2937-44. PMID 19620028 DOI: 10.1016/j.jchromb.2009.07.004 |
0.122 |
|
| 2017 |
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews. Drug Discovery. PMID 28303026 DOI: 10.1038/nrd.2016.268 |
0.122 |
|
| 2007 |
Beghin A, Galmarini CM, Dumontet C. Tubulin folding pathways: Implication in the regulation of microtubule dynamics Current Cancer Drug Targets. 7: 697-703. PMID 18220530 DOI: 10.2174/156800907783220426 |
0.122 |
|
| 2012 |
Miller LM, Huang Yang CP, Xiao H, Isaac S, Sève P, Dumontet C, Band Horwitz S, Hogue Angeletti R. A label-free mass spectrometry method for relative quantitation of β-tubulin isotype expression in human tumor tissue. Proteomics. Clinical Applications. 6: 502-6. PMID 22996942 DOI: 10.1002/prca.201200018 |
0.12 |
|
| 2003 |
Galmarini CM, Dumontet C. EPO-906 Novartis Idrugs. 6: 1182-1187. PMID 14666430 |
0.116 |
|
| 2019 |
Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, Joseph B. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chemical Science. 10: 4048-4053. PMID 31015945 DOI: 10.1039/C9Sc00285E |
0.115 |
|
| 2009 |
Crauste C, Lefebvre I, Hovaneissian M, Puy JY, Roy B, Peyrottes S, Cohen S, Guitton J, Dumontet C, Perigaud C. Development of a sensitive and selective LC/MS/MS method for the simultaneous determination of intracellular 1-beta-D-arabinofuranosylcytosine triphosphate (araCTP), cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in a human follicular lymphoma cell line. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 1417-25. PMID 19328748 DOI: 10.1016/j.jchromb.2009.02.071 |
0.115 |
|
| 2004 |
Leleu X, Troncy J, Bouafia F, Michallet M, Facon T, Dumontet C. Evaluation of gemcitabine in relapsed or refractory multiple myeloma Haematologica.. 89. PMID 15533848 |
0.115 |
|
| 2023 |
Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, Kryza D, Evesque A, Jordheim LP, Perrial E, Matera EL, ... ... Dumontet C, et al. A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models. Frontiers in Immunology. 14: 1066402. PMID 37223101 DOI: 10.3389/fimmu.2023.1066402 |
0.113 |
|
| 2021 |
Waller RG, Klein RJ, Vijai J, McKay JD, Clay-Gilmour A, Wei X, Madsen MJ, Sborov DW, Curtin K, Slager SL, Offit K, Vachon CM, Lipkin SM, Dumontet C, Camp NJ. Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics. PMID 33751038 DOI: 10.1093/hmg/ddab066 |
0.113 |
|
| 2006 |
Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 106: 2058-66. PMID 16583433 DOI: 10.1002/cncr.21833 |
0.11 |
|
| 2008 |
Jeanpierre S, Nicolini FE, Kaniewski B, Dumontet C, Rimokh R, Puisieux A, Maguer-Satta V. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood. 112: 3154-63. PMID 18664625 DOI: 10.1182/blood-2008-03-145326 |
0.11 |
|
| 2008 |
Jeanpierre S, Nicolini FE, Kaniewski B, Dumontet C, Rimokh R, Puisieux A, Maguer-Satta V. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood. 112: 3154-63. PMID 18664625 DOI: 10.1182/blood-2008-03-145326 |
0.11 |
|
| 2012 |
Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Béatrice T, Onraed B, Faucompré JL, Hennache B, Dumontet C, Facon T, Leleu X. Prognostic value of PINI index in patients with multiple myeloma. European Journal of Haematology. 88: 306-13. PMID 22126676 DOI: 10.1111/j.1600-0609.2011.01740.x |
0.108 |
|
| 2023 |
Richert I, Berchard P, Abbes L, Novikov A, Chettab K, Vandermoeten A, Dumontet C, Karanian M, Kerzerho J, Caroff M, Blay JY, Dutour A. A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages. Cancers. 15. PMID 37760603 DOI: 10.3390/cancers15184635 |
0.108 |
|
| 1997 |
Dumontet C, Rebbaa A, Portoukalian J. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice Journal of Immunological Methods. 206: 115-123. PMID 9328574 DOI: 10.1016/S0022-1759(97)00096-3 |
0.106 |
|
| 2002 |
Berthet C, Guéhenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C, Dumontet C, Magaud JP, Rouault JP. Interaction of PRMT1 with BTG/TOB proteins in cell signalling: Molecular analysis and functional aspects Genes to Cells. 7: 29-39. PMID 11856371 DOI: 10.1046/j.1356-9597.2001.00497.x |
0.106 |
|
| 2022 |
Selvy M, Mattévi C, Dalbos C, Aissouni Y, Chapuy E, Martin PY, Collin A, Richard D, Dumontet C, Busserolles J, Condé S, Balayssac D. Analgesic and preventive effects of donepezil in animal models of chemotherapy-induced peripheral neuropathy: Involvement of spinal muscarinic acetylcholine M2 receptors. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 149: 112915. PMID 35635358 DOI: 10.1016/j.biopha.2022.112915 |
0.105 |
|
| 2021 |
Canzian F, Piredda C, Macauda A, Zawirska D, Andersen NF, Nagler A, Zaucha JM, Mazur G, Dumontet C, Wątek M, Jamroziak K, Sainz J, Várkonyi J, Butrym A, Beider K, et al. A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics : Ejhg. PMID 34845334 DOI: 10.1038/s41431-021-00986-8 |
0.105 |
|
| 1999 |
Duhaut P, Pinède L, Bornet H, Demolombe-Ragué S, Dumontet C, Ninet J, Loire R, Pasquier J. Biopsy proven and biopsy negative temporal arteritis: Differences in clinical spectrum at the onset of the disease Annals of the Rheumatic Diseases. 58: 335-341. PMID 10340957 |
0.101 |
|
| 2004 |
Sève P, Renaudier P, Sasco AJ, Dumontet C, Salles G, Coiffier B, Zoulim F, Broussolle C, Trépo C. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: A cross-sectional study in Lyon, France European Journal of Gastroenterology and Hepatology. 16: 1361-1365. PMID 15618846 DOI: 10.1097/00042737-200412000-00021 |
0.1 |
|
| 2007 |
Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[f-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site Cancer. 109: 292-299. PMID 17167760 DOI: 10.1002/cncr.22410 |
0.1 |
|
| 2012 |
Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, ... ... Dumontet C, et al. Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (review) International Journal of Oncology. 40: 625-638. PMID 22159523 DOI: 10.3892/ijo.2011.1284 |
0.099 |
|
| 2021 |
Cros-Perrial E, Saulnier S, Raza MZ, Charmelot R, Egron D, Dumontet C, Chaloin L, Peyrottes S, Jordheim LP. Cytotoxic and antitumoral activity of N-(9H-purin-6-yl) benzamide derivatives and related water-soluble prodrugs. Current Molecular Pharmacology. PMID 34649495 DOI: 10.2174/1874467214666211014164406 |
0.097 |
|
| 2011 |
Ricci E, Bourrelie E, Martin X, Dumontet C, Clezardin P, Thalmann G, Colombel M. 838 TESTING AND PROGNOSTIC IMPLICATIONS OF PROSTATE CANCER STEM CELLS IN BONE MARROW European Urology Supplements. 10: 265. DOI: 10.1016/S1569-9056(11)60824-5 |
0.096 |
|
| 1999 |
Duhaut P, Pinède L, Demolombe-Ragué S, Dumontet C, Ninet J, Seydoux D, Loire R, Pasquier J. Giant cell arteritis and polymyalgia rheumatica: Are pregnancies a protective factor? A prospective, multicentre case-control study Rheumatology. 38: 118-123. PMID 10342623 DOI: 10.1093/rheumatology/38.2.118 |
0.096 |
|
| 2022 |
Chettab K, Matera EL, Lafond M, Coralie D, Favin-Lévêque C, Goy C, Strakhova R, Mestas JL, Lafon C, Dumontet C. Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. Molecular Pharmaceutics. 19: 929-935. PMID 35147436 DOI: 10.1021/acs.molpharmaceut.1c00907 |
0.095 |
|
| 1983 |
Dumontet C, Rousset B. Identification, purification, and characterization of a non-heme lactoperoxidase in bovine milk Journal of Biological Chemistry. 258: 14166-14172. PMID 6417136 |
0.094 |
|
| 1989 |
Dumontet C. Immunotherapy and cancer : Interest by monoclonal antibodies Journal De Chirurgie. 126: 682-686. PMID 2695534 |
0.094 |
|
| 2018 |
Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, et al. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. PMID 29784907 DOI: 10.1038/s41375-018-0133-x |
0.093 |
|
| 2018 |
Sut C, Hamzeh-Cognasse H, Arthaud CA, Eyraud MA, Chettab K, Dumontet C, Laradi S, Burnouf T, Garraud O, Cognasse F. Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. Transfusion. PMID 30325037 DOI: 10.1111/trf.14973 |
0.091 |
|
| 2020 |
Boyle EM, Ashby C, Tytarenko R, Deshpande S, Wang Y, Sawyer J, Tian E, Johnson S, Rutherford MW, Wardell CP, Bauer MA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, ... ... Dumontet C, et al. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31988198 DOI: 10.1158/1078-0432.Ccr-19-1507 |
0.09 |
|
| 1997 |
Allauchiche B, Jaumain H, Dumontet C, Motin J. Early diagnosis of ventilator-associated pneumonia. Is it possible to define a cut-off value of infected cells in BAL fluid? Pneumologie. 51: 511. |
0.089 |
|
| 2017 |
De Crozals G, Kryza D, Jiménez Sánchez G, Roux S, Mathé D, Taleb J, Dumontet C, Janier M, Chaix C. G-CSF nanocarriers for stimulation of the immune system (Part I): synthesis and biodistribution studies. Bioconjugate Chemistry. PMID 29283548 DOI: 10.1021/acs.bioconjchem.7b00605 |
0.088 |
|
| 1990 |
Letanche G, Dumontet C, Euvrard P, Souquet PJ, Bernard JP. Distal metastases in bronchial cancer. Bone metastases and soft tissue metastases Bulletin Du Cancer. 77: 1025-1030. PMID 2249012 |
0.087 |
|
| 2023 |
Denis M, Mathé D, Micoud M, Choffour PA, Grasselly C, Matera EL, Dumontet C. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. Frontiers in Immunology. 13: 1011943. PMID 36703964 DOI: 10.3389/fimmu.2022.1011943 |
0.087 |
|
| 2020 |
Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C. A heavy metal baseline score predicts outcome in AML. American Journal of Hematology. PMID 31944361 DOI: 10.1002/Ajh.25731 |
0.085 |
|
| 2023 |
Dumontet C, Demangel D, Galia P, Karlin L, Roche L, Fauvernier M, Golfier C, Laude MC, Leleu X, Rodon P, Roussel M, Azaïs I, Doyen C, Slama B, Manier S, et al. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study. American Journal of Hematology. 98: 264-271. PMID 36588407 DOI: 10.1002/ajh.26785 |
0.08 |
|
| 2018 |
Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, ... ... Dumontet C, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. PMID 30446495 DOI: 10.1182/Blood-2018-08-872226 |
0.075 |
|
| 2018 |
Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods (San Diego, Calif.). PMID 30453028 DOI: 10.1016/j.ymeth.2018.11.008 |
0.075 |
|
| 1992 |
Lachaux A, Loras-Duclaux I, Bouvier R, Dumontet C, Hermier M. Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity The Journal of Pediatrics. 121: 78-80. PMID 1352544 DOI: 10.1016/S0022-3476(05)82546-6 |
0.072 |
|
| 2014 |
Dhilly M, Guillouet S, Patin D, Fillesoye F, Abbas A, Gourand F, Tirel O, Galateau F, MacKenzie ET, Dumontet C, Leporrier M, Barré L. 2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 118-26. PMID 23852402 DOI: 10.1007/s11307-013-0659-2 |
0.071 |
|
| 2021 |
Chasseloup F, Bourdeau I, Tabarin A, Regazzo D, Dumontet C, Ladurelle N, Tosca L, Amazit L, Proust A, Scharfmann R, Mignot T, Fiore F, Tsagarakis S, Vassiliadi D, Maiter D, et al. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. The Lancet. Diabetes & Endocrinology. 9: 813-824. PMID 34655521 DOI: 10.1016/S2213-8587(21)00236-9 |
0.07 |
|
| 2023 |
Macauda A, Briem K, Clay-Gilmour A, Cozen W, Försti A, Giaccherini M, Corradi C, Sainz J, Niazi Y, Ter Horst R, Li Y, Netea MG, Vogel U, Hemminki K, Slager SL, ... ... Dumontet C, et al. Identification of novel genetic loci for risk of multiple myeloma by functional annotation. Leukemia. PMID 37723249 DOI: 10.1038/s41375-023-02022-8 |
0.07 |
|
| 1995 |
Marichy C, Dumontet C, Bastion Y, Rieux C, Blay JY, Salles G, Biron P, Coiffier B. Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome European Journal of Cancer. 31: 423. PMID 7786614 DOI: 10.1016/0959-8049(94)00501-U |
0.069 |
|
| 2012 |
Roy B, Vo Duy S, Puy JY, Martin C, Guitton J, Dumontet C, Périgaud C, Lefebvre-Tournier I. Synthesis and evaluation of a molecularly imprinted polymer for selective solid-phase extraction of irinotecan from human serum samples. Journal of Functional Biomaterials. 3: 131-42. PMID 24956520 DOI: 10.3390/jfb3010131 |
0.066 |
|
| 2001 |
Dumontet C. What can we expect from liposomal drugs? Annals of Oncology. 12: 433-434. PMID 11398872 DOI: 10.1023/A:1011128621302 |
0.062 |
|
| 2007 |
Khodiyar VK, Maltais LJ, Ruef BJ, Sneddon KM, Smith JR, Shimoyama M, Cabral F, Dumontet C, Dutcher SK, Harvey RJ, Lafanechère L, Murray JM, Nogales E, Piquemal D, Stanchi F, et al. A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics. 90: 285-9. PMID 17543498 DOI: 10.1016/J.Ygeno.2007.04.008 |
0.06 |
|
| 2005 |
Kagialis-Girard S, Gerland LM, Dumontet C, Treille-Ritouet D. Unusual organisms in the bone marrow of a patient with systemic sarcoidosis Laboratory Medicine. 36: 762-763. DOI: 10.1309/QB23-CHAD-ECN5-2DLM |
0.059 |
|
| 1991 |
Dumontet C, Biron F, Vitrey D, Guerin JC, Vincent M, Jarry O, Meram D, Peyramond D. Acute silicosis due to inhalation of a domestic product American Review of Respiratory Disease. 143: 880-882. PMID 2008999 |
0.058 |
|
| 1992 |
Dumontet C, Rebbaa A, Portoukalian J. Kinetics and organ distribution of [14C]-sialic acid-GM3 and [3H]-sphingosine-GM1 after intravenous injection in rats Biochemical and Biophysical Research Communications. 189: 1410-1416. PMID 1482356 DOI: 10.1016/0006-291X(92)90231-9 |
0.048 |
|
| 1994 |
Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy [3] Bone Marrow Transplantation. 14: 492-494. PMID 7994283 |
0.039 |
|
| 2010 |
Dumontet C. An eighteenth-century Italian indulgence printed on mezzo- median paper by giovanni radix of turin Script and Print. 34: 93-118. |
0.036 |
|
| 2006 |
Dumontet C. Report of the Chapbooks study day Library. 7: 105-108. DOI: 10.1093/library/7.1.105 |
0.036 |
|
| 1972 |
Hugonnier R, Magnard P, Dumontet C. Oculomotor imbalance in severe hypermetropia. (Apropos of 169 cases) Bulletin Des Societes D"Ophtalmologie De France. 72: 1045-1047. PMID 4667825 |
0.028 |
|
| 1987 |
Tissot A, Charhon A, Dumontet C, Tete R. Severe acute hepatic cytolysis due to heart disease Semaine Des Hopitaux. 63: 3447-3449. |
0.028 |
|
| 1987 |
Dumontet C, Tebib J, Noël E, Bouysset M, Colson F, Bouvier M. Tarsal bone metastasis of bladder carcinoma Annales De Radiologie. 30: 65-66. PMID 3592531 |
0.02 |
|
| 2004 |
Jeanteur P, Dumontet C. Introducing the Electronic Journal of Oncology Bulletin Du Cancer. 91: 297. |
0.011 |
|
| 2012 |
Dumontet C. Does intestinal microbiome influence the development of hepatocellular carcinoma? Bulletin Du Cancer. 99: 1105-1106. DOI: 10.1684/bdc.2012.1663 |
0.011 |
|
| 2012 |
Dumontet C, Rhodes DE. A bibliographical painting Book Collector. 61: 219-226. |
0.01 |
|
| 2011 |
Dumontet C. An unrecorded position of watermarks in early nineteenth-century english paper Script and Print. 35: 111-113. |
0.01 |
|
| 2010 |
Dumontet C. Nineteenth-century bookcloth grain classification and the special collections cataloguer Papers of the Bibliographical Society of America. 104: 105-112. |
0.01 |
|
| 2000 |
Durupt S, Durieu I, Nove-Josserand R, Dumontet C, Tognet E, Vital Durand D. Cellulite à pneumocoque révélant un myélome Revue De Medecine Interne. 21: 464-465. PMID 10874770 |
0.01 |
|
| 1991 |
Dumontet C, Vincent M, Laennec E, Girodet B, Vitrey D, Meram D, Van Straaten L. Silicosis due to inhalation of domestic cleaning powder The Lancet. 338: 1085. PMID 1681390 DOI: 10.1016/0140-6736(91)91946-R |
0.01 |
|
| 1987 |
Tebib JG, Dumontet C, Carret JP, Colson F, Bouvier M. Synovial cyst of the hip causing iliac vein and femoral nerve compression Clinical and Experimental Rheumatology. 5: 92-93. PMID 3594969 |
0.01 |
|
| Hide low-probability matches. |